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A B S T R A C T
Background
Venous leg ulcers are a common and recurring type of chronic, complex wound associated with considerable cost to patients and
healthcare providers. To aid healing, primary wound contact dressings are usually applied to ulcers beneath compression devices.
Alginate dressings are used frequently and there is a variety of alginate products on the market, however, the evidence base to guide
dressing choice is sparse.
Objectives
To determine the effects of alginate dressings compared with alternative dressings, non-dressing treatments or no dressing, with or
without concurrent compression therapy, on the healing of venous leg ulcers.
Search methods
For this first update, in March 2015, we searched the following databases: The Cochrane Wounds Group Specialised Register; The
Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed
Citations); Ovid EMBASE; and EBSCO CINAHL. There were no restrictions based on language or date of publication.
Selection criteria
Published or unpublished randomised controlled trials (RCTs) that evaluated the effects of any type of alginate dressing in the treatment
of venous ulcers were included.
Data collection and analysis
Two review authors independently performed study selection, data extraction and risk of bias assessment. Meta-analysis was undertaken
when deemed feasible and appropriate.
Main results
Five RCTs (295 participants) were included in this review. All were identified during the original review. The overall risk of bias was
high for two RCTs and unclear for three. One RCT compared different proprietary alginate dressings (20 participants), three compared
alginate and hydrocolloid dressings (215 participants), and one compared alginate and plain non-adherent dressings (60 participants).
Follow-up periods were six weeks in three RCTs and 12weeks in two. No statistically significant between-group differences were detected
for any comparison, for any healing outcome. Meta-analysis was feasible for one comparison (alginate and hydrocolloid dressings),
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with data from two RCTs (84 participants) pooled for complete healing at six weeks: risk ratio 0.42 (95% confidence interval 0.14 to
1.21). Adverse event profiles were generally similar between groups (not assessed for alginate versus plain non-adherent dressings).
Authors’ conclusions
The current evidence base does not suggest that alginate dressings are more or less effective in the healing of venous leg ulcers than
hydrocolloid or plain non-adherent dressings, and there is no evidence to indicate a difference between different proprietary alginate
dressings. However, the RCTs in this area are considered to be of low or unclear methodological quality. Further, good quality evidence
is required from well designed and rigorously conducted RCTs that employ - and clearly report on - methods to minimise bias, prior
to any definitive conclusions being made regarding the efficacy of alginate dressings in the management of venous leg ulcers.
P L A I N L A N G U A G E S U M M A R Y
Alginate dressings for venous leg ulcers
Venous leg ulcers are a common and recurring type of chronic or complex wound which can be distressing for patients and costly to
healthcare providers. Compression therapy, in the form of bandages or stockings, is considered to be the cornerstone of venous leg
ulcer management. Dressings are applied underneath bandages or stockings with the aim of protecting the wound and providing a
moist environment to aid healing. Alginate dressings contain substances derived from seaweed and are one of several types of wound
dressings available. We evaluated the evidence from five randomised controlled trials that compared either different brands of alginate
dressings, or alginate dressings with other types of dressings. In terms of wound healing, we found no good evidence to suggest that
there is any difference between different brands of alginate dressings, nor between alginate dressings and hydrocolloid or plain non-
adherent dressings. Adverse events were generally similar between treatment groups (but not assessed for alginate versus plain non-
adherent dressings). Overall, the current evidence is of low quality. Further, good quality evidence is required before any definitive
conclusions can be made regarding the use of alginate dressings in the management of venous leg ulcers.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
alginate dressing (Sorbsan®) compared to alternative alginate dressing (Tegagen ™ High Gelling) for venous leg ulceration
Patient or population: people with venous leg ulceration
Settings: outpatient clinics
Intervention: Alginate dressing (Sorbsan®)
Comparison: alternative alginate dressing (Tegagen ™ High Gelling)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Alternative
alginate dressing (Tega-
gen ™High Gelling)
Alginate dressing (Sorb-
san®)
Time to healing See comment See comment Not estimable 0
(0)
See comment Outcome not reported.
Proportion of partici-
pants with healed ulcers
Follow-up: 6 weeks
Study population1 RR 6.00
(0.32 to 111.04)
20
(1 study)
⊕©©©
very low2,3,4,5
Low1
91 per 1000 546 per 1000
(29 to 1000)
High1
204 per 1000 1000 per 1000
(65 to 1000)
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Mean change in wound
size, with adjustment for
baseline size
See comment See comment Not estimable 0
(0)
See comment Outcome not reported
(only reported mean per-
centage change in ulcer
area, with no variance es-
timate, and no adjustment
for baseline area)
Adverse effects See comment See comment Not estimable 0
(0)
See comment Limited information pro-
vided.
Health-related quality of
life
See comment See comment Not estimable 0
(0)
See comment Outcome not reported.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Note: lower risk of the outcome is less favourable (i.e. lower risk of healing) than higher risk. Estimates for baseline low and high risks
of healing at 30 days have been taken from a meta-analysis of RCTs evaluating different types of compression. The low risk estimate
is based on a subset of participants with larger baseline ulcer area (greater than 5 cm squared). The high risk estimate is based on a
subset of participants with smaller baseline ulcer surface area (5 cm squared or smaller). Most participants received a simple, low-
adherent dressing plus four-layer bandage (O’Meara 2007). Estimate of baseline risk could not be estimated from study population
because no participants healed in the Tegagen ™ HG group.
2 Overall risk of bias was unclear.
3 Risk ratio estimate based on single RCT; unable to assess heterogeneity.
4 Risk ratio estimate based on single very small RCT (N = 20).
5 Risk ratio estimate based on single RCT; unable to formally assess presence of publication bias.
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B A C K G R O U N D
For definitions of terminology see Glossary (Appendix 1).
Description of the condition
Venous leg ulcers are a common and recurring type of chronic
or complex wound. They are usually caused by venous insuffi-
ciency (impaired venous blood flow) brought about by venous
hypertension. Predisposing factors for venous hypertension in-
clude a history of deep vein thrombosis (DVT), thrombophlebitis,
leg trauma, arthritis, obesity, pregnancy and a sedentary lifestyle.
These factors can result in damage to the valves in the leg veins al-
lowingpathological two-way bloodflow instead of the normal one-
way movement. A related issue is diminished calf muscle pump ac-
tion. Both valvular and calf muscle pump impairment can result in
reduced venous blood flow leading to venous hypertension. This
causes distension of the leg veins, oedema (swelling due to fluid
accumulation) of the lower limb and leakage of circulatory fluids
from the capillaries into the surrounding tissues. This in turn in-
duces irritation and increased fragility of the epidermis (the outer
layer of skin) leading to ulceration (Doughty 2007). The duration
of venous leg ulceration ranges from a matter of weeks to more
than 10 years, and some people never heal (Moffatt 1995; Ruckley
1998; Vowden 2009a). Older patient age, longer wound duration
and larger ulcer surface area have been reported as independent
risk factors for delayed ulcer healing (Gohel 2005;Margolis 2004).
A review of 11 venous leg ulceration prevalence studies conducted
in Australia and Europe estimated point prevalence as 0.1% to
0.3% (Nelzen 2008). Surveys undertaken in the UK estimated
prevalence of venous leg ulceration as 0.023% in Wandsworth,
London (Moffatt 2004), 0.044% in Hull and East Yorkshire
(Srinivasaiah 2007), 0.039% in Bradford and Airedale (Vowden
2009a; Vowden 2009b), and 0.029% in Leeds (Hall 2014). The
lower estimates reported in the UK surveys relative to the world-
wide literature might be explained by differences in disease man-
agement or case definition, or both. The epidemiological data have
consistently suggested that prevalence increases with age and is
higher among women (Graham 2003; Lorimer 2003; Margolis
2002; Moffatt 2004; Vowden 2009a). We were unable to identify
contemporary prevalence data for non-western countries.
Diagnosis of venous leg ulceration can be made according to the
appearance and location of the ulcer. Clinical practice guidelines
recommend the use of clinical history, physical examination and
haemodynamic assessment (SIGN 2010; O’Donnell 2014). The
latter typically includes an assessment of arterial supply to the leg
using the ankle brachial pressure index (ABPI), measured using a
hand-held Doppler ultrasound scanner. Measuring ABPI in addi-
tion to visual inspection, clinical history and physical assessment
can aid confirmation of ulcer aetiology (cause). In arterial disease,
Doppler might be used to assess the extent of the arterial disease
or to confirm the diagnosis. Venous and arterial disease can co-
exist in the same person (SIGN 2010; O’Donnell 2014). An ABPI
measurement of greater than 0.8 at rest is generally used to rule
out the co-existence of clinically significant peripheral arterial dis-
ease in a leg ulcer that has been diagnosed as being due to venous
insufficiency (Moffatt 2007); some sources suggest a more strin-
gent threshold for this purpose (greater than 0.9) (SIGN 2010;
O’Donnell 2014).
Leg ulcers are associated with considerable cost to patients and
to healthcare providers. Two systematic reviews summarised the
literature on health-related quality of life in patients with leg ul-
cers (Herber 2007; Persoon 2004). Both included qualitative and
quantitative evaluations and reported that presence of leg ulcera-
tion was associated with pain, restriction of work and leisure activ-
ities, impaired mobility, sleep disturbance, reduced psychological
well-being and social isolation.
The cost of treating an unhealed leg ulcer in the UK has been
estimated to be around GBP 1300 per year at 2001 prices (Iglesias
2004). Another evaluation estimated the average cost of treating
a venous leg ulcer (based on cost of dressings) as varying between
EUR 814 and EUR 1994 in the UK and EUR 1332 and EUR
2585 in Sweden (price year 2002), with higher costs associated
with larger andmore chronic wounds (Ragnarson Tennvall 2005).
This reflected findings from a more recent evaluation conducted
in Hamburg, Germany, recruiting 502 community based adult
patients with any type of leg ulcer. The total mean annual cost of
illness for leg ulcers was estimated as EUR 9060 per patient (price
year 2006), taking account of direct, indirect and intangible costs
from a societal perspective. Direct costs included all expenses di-
rectly related to leg ulcer care (dressings, bandages, topical agents,
systemic treatment, diagnostic procedures, clinician fees, in-pa-
tient treatment costs and transport); indirect costs related to loss
of productivity; and intangible costs included impact on health-
related quality of life. Estimates ranged from zero cost (i.e. no
treatment) to EUR 44,462, with higher costs associated with ul-
cers with arterial aetiology, larger wound size and no history of
wound closure (Augustin 2012). A large part of ulcer treatment
cost comprises nursing time. For the financial year 2006-2007 in
Bradford, UK, GBP 1.69 million was spent on dressings and com-
pression bandages and GBP 3.08 million on nursing time (esti-
mates derived from resource use data for all wound types, not just
venous leg ulcers) (Vowden 2009c). We were unable to identify
additional, contemporary, international cost data.
Description of the intervention
Compression therapy (bandages or stockings) is now considered to
be the cornerstone of venous leg ulcermanagement (Moffatt 2007;
O’Meara 2012). Primary wound contact dressings (i.e. dressings
in direct contact with the wound bed) are usually applied under-
neath compression devices. A range of other interventions may be
used concurrently with compression, including debriding agents
(Davies 2005), vasoactive drugs (Robson 2006), fibrinolytic ther-
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apy (Robson 2006), physical therapies (Cullum 2010; Aziz 2015),
and topical applications (Robson 2006).
Primary wound contact dressings are applied beneath compres-
sion devices with the aim of aiding healing, providing comfort,
controlling exudate (the fluid produced by wounds) and helping
to prevent bandages and stockings from adhering to the wound
bed. The ideal conditions required for wound healing in terms
of dressing application are proposed as follows: maintenance of a
moist wound environment without risk of maceration (excessive
softening of skin because of being constantly wet); avoidance of
toxic chemicals, particles or fibres in the dressing fabric; minimi-
sation of number of dressing changes; and maintenance of an op-
timum pH level (balanced acidity and alkalinity) (BNF 2015).
Several types of wound dressing are available and costs vary
(Appendix 2). For example, there can be a six-fold difference in
the UK unit price of a 9.5 cm x 9.5 cm non-adherent (knitted
viscose) dressing compared with a 10 cm x 10 cm calcium alginate
dressing (BNF 2015).
Alginate dressings are available as flat, freeze-dried porous sheets,
or as flexible fibre dressings (e.g. packing tape), designed for pack-
ing cavity wounds. The base constituents include calcium algi-
nate or calcium sodium alginate, derived from brown seaweed.
Alginate dressings are designed to form a soft gel once in contact
with wound exudate. Purported benefits of alginate dressings in-
clude high absorbency of fluid frommoderately to heavily exuding
wounds and the ability to maintain a moist wound environment,
thereby promoting autolytic debridement (the body’s own process
of breaking down dead tissue lying on top of the wound bed).
Calcium ions present in the dressings help to control bleeding by
aiding blood clotting; a potential disadvantage is that blood clots
may cause the dressing to adhere to the wound surface. Alginate
dressings are designed to function most effectively in a moist en-
vironment, and are not suitable for use with dry wounds, or those
covered with hard, necrotic tissue; heavy bleeding is a contraindi-
cation to use (BNF 2015; Boateng 2008). In the UK, alginate
dressings are common to many wound care formularies, where
they are often recommended for the management of wounds with
moderate to high amounts of exudate.
Examples of alginate dressings currently available in the UK in-
clude Algosteril® (Smith and Nephew) and Tegaderm® Alginate
(3M). Appendix 2 provides a description of all wound dressings
categorised by the British National Formulary (BNF 2015).
How the intervention might work
Findings from research based on animal models suggest that acute
wounds heal more quickly if the wound surface is kept moist in
order to prevent the formation of a hard scab or eschar. A moist
environment is also thought to provide optimal conditions for
promoting autolytic debridement, which is sometimes considered
to be an important part of the healing pathway (König 2005). It
has been suggested that alginate dressings may control bleeding,
manage exudate, promote autolytic debridement, provide a moist
wound healing environment and promote healing (BNF 2015;
Boateng 2008).
Why it is important to do this review
Wound dressings are a key part of the treatment pathway when
caring for venous leg ulcers.Most will be used in combinationwith
compression systems and guidelines are necessary to help make
decisions regarding the value and best use of available dressings.
Several types of wound dressing are available, and costs vary con-
siderably. However, the evidence base to guide dressing choice is
sparse. A previous systematic review evaluating different wound
dressings for venous leg ulcers concluded that the type of dress-
ing applied beneath compression did not influence ulcer healing
(Palfreyman 2007). The authors concluded that there was insuf-
ficient evidence to permit firm recommendations for the use of
alginate dressings compared with other dressings.
This review updates part of the previous systematic review by
Palfreyman 2007 and is one of several Cochrane reviews investi-
gating the use of dressings in the treatment of venous leg ulcers
(O’Meara 2013; Ribeiro 2013; Ribeiro 2014).
O B J E C T I V E S
The primary objective of this review was to determine the effects
of alginate dressings compared with alternative dressings, non-
dressing treatments or no dressing, with or without concurrent
compression therapy, on the healing of venous leg ulcers. Sec-
ondary objectiveswere to determine the effects of alginate dressings
compared with alternatives on: health-related quality of life, costs
(e.g. cost-effectiveness estimations), pain (e.g. at dressing change),
debridement, haemostasis (control of bleeding), dressing perfor-
mance (management of wound exudate and ease of removal) and
adverse effects (e.g. infection, eczema, maceration).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs), either published
or unpublished, that evaluated the effects of any type of alginate
dressing in the treatment of venous ulcers, irrespective of language
of report. RCTs reported in abstract form only were eligible for
inclusion, provided adequate information was either presented in
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the abstract or available from the trial author. Studies using quasi-
randomisation were excluded.
Types of participants
We considered RCTs recruiting people described in the primary
report as having venous leg ulcers, managed in any care setting,
to be eligible for inclusion. As the method of diagnosis of venous
ulceration may vary, we accepted definitions as used in the RCTs.
We included RCTs recruiting samples that comprised people with
venous leg ulcers and people with other types of wounds (e.g.
arterial ulcers, diabetic foot ulcers) if the results for people with
venous ulcers were presented separately (or available from the trial
authors), or if the majority of participants (75% or more in each
arm) had leg ulcers of venous aetiology.
Types of interventions
The primary intervention of interest was alginate wound dress-
ings. For ease of comparison, we grouped included RCTs accord-
ing to the comparator intervention using categories presented in
the British National Formulary (BNF 2015). We have reported
generic names for all products where possible, also providing trade
names and manufacturers, where available. However, it is impor-
tant to note that manufacturers and distributors of dressings may
vary from country to country, and dressing names may also differ.
We have not included RCTs assessing alginate dressings impreg-
nated with antibiotic, antiseptic or analgesic agents as these inter-
ventions are evaluated in other Cochrane reviews (Briggs 2012;
O’Meara 2014). RCTs evaluating foam dressings, hydrocolloid
dressings and hydrogels are covered in other Cochrane reviews
(O’Meara 2013; Ribeiro 2013; Ribeiro 2014) and were included
in this review only if they involved a comparison with an alginate
dressing.
We included any RCT in which the presence or absence of an
alginate dressing was the only systematic difference between treat-
ment groups; and inwhich an alginate dressingwas comparedwith
other wound dressings (including alternative alginate dressings),
non-dressing treatments (for example, topical applications) or no
dressing. We included RCTs of alginate dressings, irrespective of
whether compression was reported as a concurrent therapy.
Types of outcome measures
Primary outcomes
The primary outcome for the review was wound healing. Wound
healing is measured and reported by trial authors in many different
ways, including time to complete wound healing, the proportion
of wounds healed during follow-up, change in wound size and
rate of change in wound size. For this review, we regarded RCTs
that reported one or more of the following as providing the best
measures of outcome in terms of relevance and rigour:
• time to complete wound healing (correctly analysed using
censored data and preferably with adjustment for prognostic
covariates such as baseline size);
• the proportion of ulcers healed during follow-up (frequency
of complete healing);
• and change (and rate of change) in wound size, with
adjustment for baseline size.
We considered evidence fromRCTs that reported mean or median
time to healing without survival analysis (i.e. they regarded time
to healing as a continuous measure without censoring), and those
that reported change or rate of change in wound size without
adjustment for baseline size, as less rigorous assessments of these
outcomes. Data reported in this manner have not been used to
populate the ’Summary of findings’ tables.
Secondary outcomes
The secondary outcomes for the review were:
• health-related quality of life (measured using a validated
standardised generic questionnaire such as EQ-5D, SF-36, SF-
12 or SF-6 or validated disease-specific questionnaire) preferably
with follow-up estimates adjusted for baseline scores;
• costs (including cost or cost-effectiveness estimations as well
as measurements of resource use such as number of dressing
changes, dressing wear time and nurse time);
• pain (e.g. at dressing change, in between dressing changes
or over the course of treatment);
• debridement (e.g. measured as percentage of sloughy or
necrotic material remaining on the wound bed);
• haemostasis (control of bleeding);
• dressing performance (exudate management and ease of
removal/adherence to the wound bed); and
• rates of adverse events together with descriptions (e.g.
infection, eczema, maceration).
Search methods for identification of studies
Electronic searches
In March 2015, for this first update, we searched the following
electronic databases for potentially relevant RCTs:
• The Cochrane Wounds Group Specialised Register
(searched 4 March 2015);
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2015, Issue 2);
• Ovid MEDLINE (1946 to 3 March 2015);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations searched 3 March 2015);
• Ovid EMBASE (1980 to 3 March 2015);
• EBSCO CINAHL (1982 to 4 March 2015)
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We used the following search strategy in the Cochrane Central
Register of Controlled Trials (CENTRAL):
#1 MeSH descriptor Alginates explode all trees
#2 (alginate* or activheal or algisite or algosteril or curasorb or
kaltostat or melgisorb or seasorb or sorbalgon or sorbsan or supra-
sorb a or tegaderm or tegagel or urgosorb):ti,ab,kw
#3 (#1 OR #2)
#4 MeSH descriptor Leg Ulcer explode all trees
#5 ((varicose NEXT ulcer*) or (venous NEXT ulcer*) or (leg
NEXT ulcer*) or (stasis NEXT ulcer*) or (crural NEXT ulcer*)
or “ulcus cruris” or “ulcer cruris”):ti,ab,kw
#6 (#4 OR #5)
#7 (#3 AND #6)
We adapted this strategy to search Ovid MEDLINE, Ovid
EMBASE and EBSCO CINAHL (Appendix 3). We combined
the Ovid MEDLINE search with the Cochrane Highly Sensi-
tive Search Strategy for identifying randomised trials in MED-
LINE: sensitivity- and precision-maximising version (2008 revi-
sion) (Lefebvre 2011). We combined the EMBASE search with
the Ovid EMBASE filter developed by the UK Cochrane Centre
(Lefebvre 2011). We combined the CINAHL searches with the
trial filters developed by the Scottish Intercollegiate Guidelines
Network (SIGN 2014). We did not restrict searches with respect
to language or date of publication.
We searched for ongoing RCTs in the following clinical trial reg-
istries using the search term ’leg ulcer’:
• World Health Organization International Trial Registry
Platform (http://www.who.int/ictrp/en/);
• ISRCTN (International Standard Randomised Controlled
Trial Number) register (http://www.controlled-trials.com/);
• ClinicalTrials.gov (http://www.clinicaltrials.gov).
All registries were accessed on 1st August 2012 for the original
review and on 17th July 2015 for this update.
Searching other resources
We attempted to contact trial authors to obtain unpublished data
and other information as required. For the first version of this
review, we contacted manufacturers to request information about
ongoing or unpublished RCTs (for a list of manufacturers see
Appendix 4).We also examined the reference lists of eligible RCTs
and relevant review articles.
Data collection and analysis
Selection of studies
Two review authors independently assessed the titles and abstracts
for relevance. After this initial assessment, we obtained the full
text of all RCT reports felt to be potentially relevant. Two review
authors then independently checked the full papers for eligibility,
with all disagreements resolved by discussion. We recorded all
reasons for exclusion.
We have presented our study selection process as a PRISMA (Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analy-
ses) flow diagram (Liberati 2009) (Figure 1).
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Figure 1. Flow diagram of the trial selection process.
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Data extraction and management
We extracted and summarised details of the eligible RCTs using
a standardised data extraction form (Appendix 5). We extracted
the data from RCT reports using an Excel spreadsheet designed to
capture the RCT information detailed below. Initially, we piloted
the spreadsheet with a sample of eligible RCTs, to explore any
issues that might arise in relation to the data extraction process.
We expanded and amended the spreadsheet as necessary after the
piloting process. Two review authors performed independent data
extraction of all included RCTs after which both data extractions
were compared for agreement. We resolved any disagreements by
discussion. If data were missing from reports we attempted to con-
tact the trial authors to obtain the missing information. We in-
cluded RCTs published as duplicate reports (parallel publications)
once, using all associated RCT reports to extract the maximum
amount of information, but ensuring that data were not dupli-
cated in the review. We extracted the following information:
• trial authors;
• year of publication;
• country where trial was undertaken;
• setting of care;
• trial design details (e.g. pragmatic, pilot);
• ethical approval;
• participant consent;
• unit of investigation - participant, leg or ulcer;
• overall sample size and methods used to estimate statistical
power (relates to the target number of participants to be
recruited, the clinical difference to be detected and the ability of
the RCT to detect this difference);
• participant selection criteria;
• number of participants randomised to each treatment arm;
• baseline characteristics of participants per treatment arm
(gender, age, baseline ulcer area, ulcer duration, prevalence of co-
morbidities such as diabetes, prevalence of clinically infected
wounds or colonised wounds, previous history of ulceration,
baseline levels of wound exudate, and participant mobility);
• details of the dressing/treatment regimen prescribed for
each arm including details of any concomitant therapy, for
example, compression;
• duration of treatment;
• duration of follow-up;
• statistical methods used for data analysis;
• primary and secondary outcomes measured;
• primary and secondary outcome data by treatment arm;
• adverse effects of treatment (per treatment arm with
numbers and type);
• withdrawals (per treatment arm with numbers and reasons);
and
• source of trial funding.
Assessment of risk of bias in included studies
Two review authors independently assessed each included RCT
report using The Cochrane Collaboration tool for assessing risk of
bias (Higgins 2011). This tool addresses specific domains, namely:
sequence generation, allocation concealment, blinding of partici-
pants and personnel, blinding of outcome assessment, incomplete
outcome data and selective outcome reporting (see Appendix 6
for details of the criteria on which judgements were based). For
blinded outcome assessment we made separate judgements for
primary and secondary outcomes. As assessment of healing (the
primary outcome) is likely to be subject to potential observer/
measurement bias, blinding of outcome assessment is important.
Similarly wemade separate judgements for primary and secondary
outcomes for the domain of incomplete outcome data. In order
to assess selective outcome reporting, we sought protocols for all
included RCTs. Where protocols were unavailable, we made a
judgement based on congruence of information in methods and
results sections of reports of RCTs. We classified RCTs as being at
overall high risk of bias if they were rated as ’high’ for any one of
three key domains (allocation concealment, blinding of outcome
assessors and completeness of outcome data).
We have presented our assessment of risk of bias findings using
’Risk of bias’ figures (Figure 2 is a summary of information across
all included RCTs and Figure 3 shows a cross-tabulation of each
individual RCT with each risk of bias item). This display of inter-
nal validity indicates the weight the reader may give the results of
each RCT.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included trials.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
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Measures of treatment effect
We reported estimates for dichotomous outcomes (e.g. number of
ulcers healed) as risk ratio (RR) with associated 95% confidence
interval (CI).We reported estimates for continuous data outcomes
(e.g. absolute or relative change in ulcer area and healing rate) as
mean difference (MD) with 95% CI. We planned to report esti-
mates of time to healing and hazard ratios where available. Where
RCTs reported adverse events in sufficient detail (e.g. the num-
ber of participants who experienced at least one adverse event) we
analysed these data as dichotomous. Where adverse events were
reported as dressing-related we planned to analyse these data sep-
arately. We calculated measures of effect using Cochrane RevMan
software (version 5.1) (RevMan 2014). We reported data narra-
tively as provided in the RCT reports, without additional estima-
tion of treatment effect, in the following instances:
• where time to healing estimates were based on non-
censored data;
• where count data were provided (e.g. where the
denominator was the total number of adverse events or total
number of dressing changes per group);
• and where it was unclear whether the denominator was the
total number of events (such adverse events or dressing changes)
or the number of participants.
Unit of analysis issues
We recorded whether RCT reports specified participants, limbs
or ulcers as the units of allocation and analysis. In cases where
multiple limbs or ulcers on the same individual were studied, we
planned to note whether the trial authors’ analysis was appropriate
(i.e. correctly taking account of highly correlated data) or inappro-
priate (i.e. considering outcomes for multiple ulcers on the same
participant as independent). Where the number of wounds ap-
peared to be equal to the number of participants, we have assumed
that the ulcer was the unit of analysis, unless otherwise stated.
Dealing with missing data
Missing data are a common problem in RCTs. Excluding ran-
domised participants from the analysis, or ignoring those lost to
follow-up, can compromise the process of randomisation and in-
troduce bias.Where RCTs reported the outcome of complete heal-
ing only for participants who completed the RCT (i.e. partici-
pants withdrawing and lost to follow-up were excluded from the
analysis), we treated the excluded participants as if their wound
did not heal (that is, they were included in the denominator but
not the numerator). Where results were reported for participants
who completed the RCT without specifying the numbers initially
randomised per group, we presented complete case data. For other
outcomes we presented data for all participants randomised where
reported; otherwise we based our estimates on complete case data.
Assessment of heterogeneity
We considered clinical heterogeneity (that is the degree to which
RCTs vary in terms of participant, intervention and outcome char-
acteristics) and statistical heterogeneity.We assessed statistical het-
erogeneity using the Chi² test (a significance level of P < 0.10
was considered to indicate statistically significant heterogeneity)
in conjunction with the I² statistic (Higgins 2003). The I² statis-
tic examines the percentage of total variation across RCTs that
is due to heterogeneity rather than chance (Higgins 2003). We
considered that I² values of 40%, or less, indicated a low level of
heterogeneity, and values of 75%, or more, indicated very high
heterogeneity (Deeks 2011).
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influenced by the nature and direction of results. Publication
bias is one of a number of possible causes of ’small study effects’,
that is, a tendency for estimates of the intervention effect to be
more beneficial in smaller RCTs. Funnel plots allow a visual as-
sessment of whether small study effects may be present in a meta-
analysis. A funnel plot is a simple scatter plot of the intervention
effect estimates from individual RCTs against some measure of
each trial’s size or precision (Sterne 2011). We planned to present
funnel plots for meta-analyses comprising 10 RCTs or more using
RevMan 5.1.
Data synthesis
We have presented a narrative synthesis of all included RCTs, with
results grouped according to type of comparator (e.g. foam dress-
ings compared with alginates, hydrocolloids compared with algi-
nates).Weundertook statistical pooling of outcomedata on groups
of RCTs with available data and considered to be sufficiently sim-
ilar in terms of design and characteristics of participants, inter-
ventions and outcomes. The decision to undertake meta-analysis
depended on the availability of outcome data and assessment of
heterogeneity. For comparisons where there was no apparent clin-
ical heterogeneity and the I² value was 40%, or less, we applied
a fixed-effect model. Where there was no apparent clinical het-
erogeneity and the I² value was over 40%, we planned to apply
a random-effects model. However, we planned not to pool data
where heterogeneity was very high (I² values of 75% or above).
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For dichotomous outcomes we have presented the summary esti-
mate as a risk ratio (RR) with 95% CI. Where continuous out-
comes were measured in the same way across RCTs, we planned
to present a pooled mean difference (MD) with 95% CI; we
planned to pool standardised mean difference (SMD) estimates
where RCTs measured the same outcome using different meth-
ods. For time to event data, we planned to plot (and, if appro-
priate, pool) estimates of hazard ratios and 95% CIs as presented
in the RCT reports using the generic inverse variance method in
RevMan 5.1. Where hazard ratios were not reported we planned
to extrapolate estimates, where possible, using other reported data
(Parmar 1998). Pooled estimates of treatment effect were obtained
using Cochrane RevMan software (version 5.1) (RevMan 2014).
’Summary of findings’ tables
We have presented the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach.
The GRADE approach defines the quality of a body of evidence as
the extent to which one can be confident that an estimate of effect
or association is close to the true quantity of specific interest. The
quality of a body of evidence involves consideration of within-
trial risk of bias (methodological quality), directness of evidence,
heterogeneity, precision of effect estimates and risk of publication
bias (Schünemann 2011b). We planned to present the following
outcomes in the ’Summary of findings’ tables:
• time to complete ulcer healing where analysed using
appropriate survival analysis methods;
• proportion of ulcers completely healing during the trial
period;
• change in wound size, when adjusted for baseline size;
• adverse events; and
• health-related quality of life.
Subgroup analysis and investigation of heterogeneity
We planned to conduct a subgroup analysis for complete heal-
ing according to whether compression was used as a concurrent
treatment, excluding any RCTs in which use of compression was
unclear.
Sensitivity analysis
We planned two sensitivity analyses for the outcome of complete
healing: one where RCTs classified as being at overall high risk of
biaswere excluded; andonewhereRCTs that possibly, or definitely,
reported outcomes only for participants who completed the trial
were excluded.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The total number of records identified from the search strategy
is 569; the breakdown in relation to the original review and this
update is as follows. For the original review, the search strategy
generated 293 records in total. Of these, 114 were retrieved from
electronic bibliographic databases, 174 from registers of ongoing
trials, and five from examination of reference lists. No references
were obtained as a result of contact with wound dressing manu-
facturers (Appendix 4). Two manufacturers out of 11 contacted
confirmed that there were no ongoing or recently completed RCTs
of alginate dressings; no replies were received from the remain-
der. Two hundred and fifty-three records were excluded because
of irrelevance on the basis of information in titles and abstracts or
records of ongoing trials (all records of ongoing trials were deemed
irrelevant). Forty records were retrieved as full text reports (all were
published). Following assessment of full text reports against the
review’s study selection criteria, 31 were excluded that reported
21 unique studies. Five RCTs (described in nine full text reports)
were included in the review (see next section for further details).
No studies were classified as awaiting assessment, or ongoing.
Reasons for exclusion of full text reports (21 unique studies) were
as follows:
• seven did not undertake a relevant comparison (Capillas
Pérez 2000; de la Brassinne 2006; Límová 2002; Romanelli
2008; Romero-Cerecero 2012; Sibbald 2005; Wild 2010);
• five indicated that the dressing was not the only systematic
difference between the treatment groups (Bull 1996;
Dmochowska 1999; Schulze 2001; Scurr 1994; Stacey 1997);
• four were reported as abstracts with limited information,
and the full RCT report was not available (Chaloner 1992;
Kammerlander 2000; Mulder 1995; Petres 1994);
• four studies were not RCTs (Anonoymous 1997;
Kordestani 2008; Moody 1991; Thomas 1989);
• and one was an animal study (Barnett 1987).
See Characteristics of excluded studies for further information.
For this first review update, database searching generated 13
records. All were excluded after screening titles and abstracts. Two
hundred and sixty three records were identified from registers of
ongoing trials; all were irrelevant to the review.
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The study selection process in shown in Figure 1.
Included studies
Five RCTs (295 participants) were included (Armstrong 1997;
Harding 2001; Límová 2003; Moffatt 1992; Smith 1994). One
was undertaken in the USA (Límová 2003), one in France and
the UK (Armstrong 1997), and the remaining three solely in the
UK (Harding 2001;Moffatt 1992; Smith 1994). Three were mul-
ticentre RCTs (Armstrong 1997; Harding 2001; Límová 2003).
One RCT was described as a pilot study (Moffatt 1992). The in-
cluded RCTs were reported between 1992 and 2003.
Sample sizes ranged from20participants to 131 participants.Only
one RCT reported performing a sample size calculation (Harding
2001). The participant was the unit of randomisation and analysis
in all five RCTs.
Where reported, the mean age of participants ranged from 73.1
years to 76.6 years. One RCT did not report on the age of the
participants (Smith 1994). The proportion of female participants
ranged from 47% to 71%. Only one RCT reported on participant
mobility, stating that 55% of participants recruited had limited
mobility or were immobile (Armstrong 1997).
With the exception of two RCTs that recruited participants with
ulcers of venous, mixed or other aetiology (Armstrong 1997;
Harding 2001), all participants had leg ulcers that were of venous
aetiology. An ABPI of less than 0.8 was an exclusion criterion in
two RCTs (Límová 2003; Moffatt 1992). Where reported, ulcer
aetiology was assessed using Doppler or patient history, or both.
The dressing comparisons evaluated by the included RCTs were
as follows:
• one RCT compared one alginate dressing (Tegagen™ HG)
with another (Sorbsan®) (Límová 2003);
• three RCTs compared hydrocolloid dressings with alginate
dressings (Armstrong 1997; Harding 2001; Smith 1994);
• and one RCT compared a plain non-adherent dressing with
an alginate dressing (Moffatt 1992).
All RCTs reported that all participants received compression ther-
apy as part of the intervention, and so the planned subgroup anal-
ysis according to use versus non use of compression as a concur-
rent treatment with dressings could not be undertaken. Length of
treatment was six weeks in three RCTs (Armstrong 1997; Límová
2003; Smith 1994), and twelve weeks in two (Harding 2001;
Moffatt 1992). Treatment settings were outpatient clinics, derma-
tology departments and the community.
All RCTs reported the proportion of ulcers completely healed at
the end of treatment. Time to complete ulcer healing was assessed
by two RCTs (Harding 2001; Moffatt 1992), and change in ulcer
size was assessed by four RCTs (Armstrong 1997; Harding 2001;
Límová 2003; Smith 1994).
See Characteristics of included studies for further details.
Risk of bias in included studies
A summary of the risk of bias assessment is presented in Figure 2
and Figure 3.
Allocation
Generation of the randomisation sequence
None of the included RCTs reported a method for generation
of the randomisation sequence, and were, therefore, all judged as
being at unclear risk of bias for this domain.
Concealment of the allocation process
Two RCTs reported the use of sealed envelopes, but did not report
whether these were opaque and sequentially numbered, and were,
therefore, judged as being at unclear risk of bias for this domain
(Armstrong 1997; Harding 2001). The remaining RCTs did not
report on the method of allocation concealment at all, and were
also considered as being at unclear risk of bias.
Blinding
Blinding of participants and personnel
Four of the included RCTs were described as ‘open’ but did not
provide any statements regarding blinding of participants or study
personnel, and were, therefore, judged as being at unclear risk of
bias for this domain (Armstrong 1997; Harding 2001; Límová
2003; Smith 1994). The RCT byMoffatt 1992 provided no state-
ment regarding blinding of participants or study personnel, and
was also judged at being unclear risk of bias.
Blinding of outcome assessment
Four of the included RCTs did not provide any statement regard-
ing blinding of outcome assessment, and were, therefore, judged
as being at unclear risk of bias for this domain (Armstrong 1997;
Harding 2001; Límová 2003; Smith 1994). The RCT report by
Moffatt 1992 indicated that the outcome assessment was not
blinded and was judged to be at a high risk of bias for this domain.
Incomplete outcome data
Three of the included RCTs described analysis on an intention-
to-treat basis and were considered to be at a low risk of bias for this
domain (Armstrong 1997; Harding 2001; Moffatt 1992). One
RCT reported that only one participant who left the trial in the
first weekwas not included in the analysis, and was also considered
to be at a low risk of bias (Límová 2003). The RCT by Smith 1994
15Alginate dressings for venous leg ulcers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
stated that the analyses excluded 12 participants who withdrew
from the trial, so was judged to be at a high risk of bias.
Selective reporting
We were unable to obtain any RCT protocols, and so judgements
were based on agreement between themethods and results sections
of RCT reports.OneRCT presented results for all of the outcomes
described in the methods section of the report and was classified
as being at a low risk of bias (Límová 2003). The remaining RCTs
were classified as being at high risk of bias for this domain, for the
following reasons.
Armstrong 1997 reported anoutcome thatwas not described in the
methods section (seven-day wear time). Conversely, there were no
data reported for two outcomes relating to dressing performance
(exudate handling and ease of removal) that were mentioned in
the methods section of the secondary reference.
Harding 2001 mentioned that secondary outcomes were assessed
by both participants and investigators, but only presented one set
of results for which the assessor was not specified. The full range
of data were not provided for the outcome of ease of dressing
removal, which used a four-point scale for assessments; only the
proportion recorded as ’excellent’ was presented.
Moffatt 1992 indicated that time to healing was assessed, but
minimal information was presented (no data and no P value).
Smith 1994 described assessing the mean number of dressing
changes, but did not report the results as mean values (ranges were
provided). Health-related quality of life was assessed using a five-
point scale but only the proportion of participants reporting the
most favourable outcome category was presented at the end of the
trial. Similarly, the full range of data for dressing performance out-
comes (exudate handling and ease of removal) were not provided.
Overall risk of bias
Two RCTs were considered as being at high risk of bias overall
(Moffatt 1992; Smith 1994), and the other three were classified
as unclear (Armstrong 1997; Harding 2001; Límová 2003).
Effects of interventions
See: Summary of findings for the main comparison Alginate
dressing (Sorbsan®) compared to alternative alginate dressing
(Tegagen™High Gelling) for venous leg ulceration; Summary of
findings 2Alginate dressing compared tohydrocolloiddressing for
venous leg ulceration; Summary of findings 3 Alginate dressing
compared to plain non-adherent dressing for venous leg ulceration
Five RCTs that evaluated alginate dressings were included in this
review (Armstrong 1997; Harding 2001; Límová 2003; Moffatt
1992; Smith 1994). The results are grouped according to the com-
parator dressing, starting with alginate dressings compared with
alternative alginate dressings (Límová 2003). This is followed by
comparisons with hydrocolloid (Armstrong 1997; Harding 2001;
Smith 1994), and plain non-adherent dressings (Moffatt 1992).
Details of primary and secondary outcome data are presented in
Table 1 and Table 2. Reporting of secondary outcomes was often
inadequate, with no presentation of variance estimates or results
of tests of statistical significance between treatment groups; where
available, we have reported these values below.
We were unable to undertake several of our planned analyses be-
cause of a lack of data available. These analyses included plotting
and pooling hazard ratio estimates, separate analyses for dressing-
and non-dressing-related adverse events, and assessment of publi-
cation bias using funnel plots. Meta-analyses of continuous data
and the planned sensitivity analyses could not be performed for
the same reason.
Comparison between different alginate dressings
OneRCTthat compareddifferent alginate dressings was identified
(Límová 2003), and classified as having an unclear overall risk of
bias.
Primary outcomes
Proportion of ulcers completely healed
Límová 2003 randomised 20 participants: 11 received a Tegagen
™ high-gelling (HG) alginate dressing and nine received a Sorb-
san® alginate dressing. The potential difference between these
dressings was not clear from the RCT report, and there was no
stated rationale for comparing them. Product information does
not draw attention to any obvious differences (3M Healthcare
2010; SMTL 2002). All participants received a secondary dress-
ing (hydrocolloid), and compression consisting of a paste bandage
covered by an elastic cohesive bandage. Participants were assessed
every seven days for six weeks, or until the ulcer no longer required
the use of an alginate dressing. It should be noted that some par-
ticipants were recruited with ulcer areas smaller than the size de-
scribed as eligible for inclusion to the trial (the specified eligible
range was 3 cm2 to 100 cm2). The number of ulcers healed at six
weeks was 0/11 (0%) in the Tegagen™HG group compared with
2/9 (22%) in the Sorbsan® group. The between-group difference
in the proportion of ulcers healed at six weeks was not statistically
significant (RR 6.00, 95% CI 0.32 to 111.04) (Analysis 1.1).
Change in ulcer size
Themean percentage change in ulcer area at six weeks was -33.7%
in the Tegagen ™ HG alginate dressing group compared with -
29.6% in the Sorbsan® alginate dressing group (Límová 2003).
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Secondary outcomes
Costs (resource use): number of dressing changes
Límová 2003 reported that 69 (65 scheduled and four unsched-
uled) dressing changes occurred in the Tegagen ™ HG alginate
dressing group compared with 61 (60 scheduled and one unsched-
uled) in the Sorbsan® alginate dressing group.
Pain
The between-group differences in comfort score, both during
dressing wear time and at dressing removal, were both statisti-
cally significant in favour of the Tegagen ™ HG alginate dress-
ing (score range 1 to 5, lower score better). The respective dif-
ferences in means were: -0.90 (95% CI -1.29 to -0.51), P value
< 0.00001 (Analysis 1.2); and -0.70 (-0.88 to -0.52), P value <
0.00001 (Analysis 1.3) (Límová 2003).
Debridement
There were no statistically significant between-group differences in
the percentage of visits where necrotic tissue was observed (Tega-
gen ™ HG 60%, Sorbsan® 69%, P value 0.57), or in the per-
centage of visits where debridement was required (19% and 41%
respectively, P value 0.18). Improvement in necrotic tissue was
measured using a scale of 0 (none) to 5 (100%); mean scores were
2.5 and 1.5 respectively, again with no statistically significant dif-
ference observed between treatment groups (P value 0.38) (all P
values as reported by trial author) (Límová 2003).
Dressing performance
Límová 2003 reported a statistically significant between-group dif-
ference in favour of Tegagen ™HG for exudate absorption score
(score range 1 to 5, lower score better): difference in means -0.80
(95% CI -1.22 to -0.38), P value 0.0002 (Analysis 1.4). However,
the difference between groups for percentage of clinic visits with
medium or large amounts of exudate observed was not statistically
significant (72% for Tegagen™HG, 86% for Sorbsan® (P value
0.25, reported by trial author).
The between-group difference for ease of dressing removal was in
also favour of Tegagen ™ HG (score range 1 to 5, lower score
better): difference in means -0.90 (95% CI -1.28 to -0.52), P
value < 0.00001 (Analysis 1.5). No participants in the Tegagen
™HG dressing group reported dressing adherence to the wound,
but 28% in the Sorbsan® group did (P value < 0.05, reported by
trial author).
Adverse events
There was a statistically significantly lower percentage of clinic vis-
its with observations of denuded peri-wound skin in the Tegagen
™ HG group than in the Sorbsan® group (9% versus 32%, P
value 0.04). However, no statistically significant between-group
differences were observed for visits with observation of maceration
or peri-wound skin requiring medication, respective values being:
36% versus 54% (P value 0.30); and 31% versus 65% (P value
0.07 - all P values as reported by trial author) (Límová 2003).
Comparison between different alginate dressings: summary
of results
Evidence from one RCT of overall unclear risk of bias suggested
no statistically significant difference between Tegagen™HG and
Sorbsan® alginate dressings in the proportion of ulcers completely
healed at six weeks (Límová 2003). In terms of secondary out-
comes, Tegagen ™ HG appeared to be statistically significantly
better than Sorbsan® for pain/comfort scores, exudate absorption
score, ease of removal, adherence to the wound bed and instances
of denuded peri-wound skin. Groups did not differ for other ad-
verse effects (maceration and requirement for medication for peri-
wound skin) or for outcomes relating to debridement. Costs (in
terms of resource use, i.e. number of dressing changes) also ap-
peared to be similar between groups, but data were difficult to
interpret because no variance estimate or P value were provided.
All data should be interpreted with caution because of the small
number of participants recruited (n = 20).
Hydrocolloid dressings compared with alginate
dressings
We identified three RCTs that compared hydrocolloid dressings
with alginate dressings, one judged to be at high overall risk of bias
(Smith 1994), and the other two classified as unclear (Armstrong
1997; Harding 2001).
Primary outcomes
Time to healing
Harding 2001 recruited participants with various types of leg ul-
cers, but the majority (79%) had venous ulceration. After ran-
domisation, 66 participants received a fibrous hydrocolloid dress-
ing, and 65 an alginate dressing. All participants had an absorbent
pad as a secondary dressing and those eligible for compression re-
ceived orthopaedic padding and a high-compression elastic ban-
dage. Participants were assessed every seven days for a maximum
of 12 weeks, or until the ulcer healed. Time to healing estimates
based on healed participants only, generated the following values:
mean days to healing were 41.8 (standard deviation (SD) 21.3) for
hydrocolloid and 56.6 (SD 21.6) for alginate dressings (P value
0.053); respective median values (ranges) were 42 (14 to 87) and
56 (14 to 85) days. The trial authors mentioned undertaking an
analysis of Kaplan-Meier survival curves based on all randomised
participants. The results of this analysis were not presented in full;
the log rank test for the difference between curves generated a P
value of 0.05.
Proportion of ulcers completely healed
Smith 1994 randomised 40 participants; 22 received a hydrocol-
loid dressing and 18 an alginate dressing. Compression bandaging
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was applied to each participant, but no details of the type used
were reported. Treatment continued for six weeks, or until the
ulcer healed. The number of ulcers healed at six weeks was 4/22
(18%) in the hydrocolloid dressing group compared with 2/18
(11%) in the alginate dressing group.
Armstrong 1997 recruited 44 participants with leg ulcers of dif-
ferent aetiologies, the majority being venous (82%). Twenty-one
participants were randomised to receive a fibrous hydrocolloid
dressing and 23 to receive an alginate dressing. All participants
received an occlusive hydrocolloid dressing as a secondary dressing
and compression (orthopaedic padding followed by a high com-
pression elastic bandage). Participants were assessed on days 14
and 28, and on completion of the trial period. Treatment was for
six weeks, or until healing if sooner. At six weeks the number of
ulcers healed in the hydrocolloid dressing group was 6/21 (29%)
compared with 2/23 (9%) in the alginate dressing group.
When these two RCTs were pooled, no statistically significant
between-group difference was detected: RR 0.42 (95% CI 0.14 to
1.21), Chi2 test for heterogeneity P value 0.53, I2 = 0% (Analysis
2.1, Figure 4).
Figure 4. Forest plot of comparison: 2 Hydrocolloid dressings compared with alginate dressings, outcome:
2.1 Proportion of ulcers healed at 6 and 12 weeks.
In the RCTbyHarding 2001, 17 participants (26%) had healed in
both groups at 12 weeks: RR 1.02 (95%CI 0.57 to 1.81) (Analysis
2.1, Figure 4).
Change in ulcer size
At six weeks Smith 1994 reported a mean percentage change in
ulcer area of -57.1% in the hydrocolloid dressing group compared
with -34.9% in the alginate dressing group. The trial authors re-
ported that the between-group difference was not statistically dif-
ferent, but the P value was not provided.
At six weeks Armstrong 1997 reported a median change in ulcer
area of -205 mm2 in the hydrocolloid dressing group compared
with -162 mm2 in the alginate dressing group. In terms of per-
centage change in area from baseline, the respective values were -
42% and -26%. The trial authors reported that the between-group
difference was not statistically significant for either outcome, but
P values were not provided.
At 12 weeks Harding 2001 reported a mean change in ulcer area
of -516.86 (SD 1202.72) mm2 in the hydrocolloid dressing group
compared with -347.30 (SD 1382.69) mm2 in the alginate dress-
ing group. The between group difference in means was not sta-
tistically significant: MD -169.56 (95% CI -613.61 to 274.49)
(Analysis 2.2). In terms of percentage change in area from base-
line, the finding was similar with mean respective values being -
38.18% (SD 92.36) and -30.54 (SD 84.08), generating MD -
7.64% (95% CI -37.88 to 22.60) (Analysis 2.3).
Secondary outcomes
Health-related quality of life
In one RCT, 42.9% of participants in the hydrocolloid dressing
group improved markedly (to the fifth category of a five-point
scale) comparedwith 40.0%of participants in the alginate dressing
group. The trial authors did not report the number of participants
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completing the quality of life assessment, and the measurement
instrument was not specified (Smith 1994).
Costs (resource use): mean wear time/number of dressing
changes
Smith 1994 reported that both dressings were equivalent in terms
of mean wear time, but no data by group, or P value for the
between-group difference, were reported.
Armstrong 1997 reported a mean wear time of four days in the hy-
drocolloid group compared with three days in the alginate group,
and the number of participants achieving a seven-daywear time on
at least one occasion was 9/21 (43%) and 3/23 (13%) respectively.
The between-group differences for both outcomes were described
as statistically significant in the RCT report, but P values were not
presented.
During the Harding 2001 trial, the total number of dressing
changes was 1093 in the hydrocolloid dressing group compared
with 1186 in the alginate group. Respective values for mean num-
ber of dressing changes per healed ulcer were 7.4 and 12.1, whilst
mean wear times for all ulcers (healed and unhealed) were 3.632
(SD 1.878) and 3.271 (SD 1.944) days. Although the RCT report
presented the latter between-group difference as statistically sig-
nificant, this was not confirmed by the review authors’ calculation
in RevMan: (MD 0.36, 95% CI -0.29 to 1.02) (Analysis 2.4).
Cost: material costs
Smith 1994 reported on cost of materials used at each dressing
change, but did not include nursing time. The mean cost in the
hydrocolloid group was GBP 431.73 compared with GBP 364.08
in the alginate group (price year/tariff not provided).
Armstrong 1997 reported a total cost per treatment group to
achieve ulcer healing based on material costs (1995 Drug Tariff )
and nursing time. The estimated cost to heal one ulcer was GBP
237.66 in the hydrocolloid dressing group compared with GBP
687.31 in the alginate dressing group (values calculated by review
authors from information in the RCT report).
Harding 2001 reported a mean cost to achieve ulcer healing based
on material costs (2000 Drug Tariff ) and nursing time of GBP
1184.09 (USD 1699.71) in the hydrocolloid dressing group com-
pared with GBP 1200.73 (USD 1723.59) in the alginate dressing
group.
Pain
Smith 1994 used an 11-point visual analogue scale, that ranged
from 0 (no pain) to 10 (worst possible pain), to assess pain at
baseline and at six weeks; both assessments were based on pain
experienced during the previous two weeks. In addition, the trial
evaluated pain during dressing change. Mean scores at baseline
appeared comparable: 4.74 for hydrocolloid and 4.86 for alginate
dressing. The changes from baseline at six weeks were -3.28 and -
2.71 respectively (calculated by review authors). The mean scores
at dressing change assessed at week six were 1.73 and 2.16, respec-
tively.
In the Armstrong 1997 trial, pain at dressing change was recorded
as one of seven categories (i.e. no pain, mild pain, moderate pain,
severe pain, excruciating pain, unable to respond, missing data).
The proportion of dressing changes across these categories ap-
peared to be similar between treatment groups, the majority of
dressing changes were associated with no pain (79%) or mild pain
(16%) (Table 2).
Harding 2001 used a four-point scale, that ranged from ’no pain’
to ’severe pain’, to assess pain during dressing removal. The per-
centage of dressing changes associated with no pain was 82% in
the hydrocolloid dressing group compared with 62% in the algi-
nate dressing group (trial authors reported P value < 0.001 for the
between-group difference). The trial authors did not provide full
data from all parts of the scale, or present raw data (so denomina-
tors for calculations were unclear).
Dressing performance: exudate handling
Harding 2001 used a four-point scale, that ranged from ’poor’
to ’excellent’, to assess exudate handling. A rating of ’excellent’
was given in 44% of instances in the hydrocolloid dressing group
compared with 20% in the alginate dressing group, however, it was
unclear whether the denominator was the number of participants
or the number of dressing changes (P value 0.002 reported by
RCT authors for the between-group difference).
Smith 1994 provided minimal details of assessment of exudate
handlingperformance, andmentioned only that the alginate dress-
ing was ’slightly superior’ in terms of ability to contain exudate.
Dressing performance: sticking/adherence
In the Smith 1994 RCT, ease of dressing removal was assessed
using a six-point scale that ranged from ’excellent’ to ’awful’. The
proportion of participants reporting ’excellent’ for ease of dressing
removal was 56.3% in the hydrocolloid dressing group compared
with 8.3% in the alginate dressing group (trial authors’ reported
P value for between-group difference < 0.001). The RCT authors
did not report raw numbers, and so it was not clear whether the
denominator was the number of participants or number of dress-
ing changes, they also did not provide the findings from the full
assessment scale.
Harding 2001 reported a percentage recording of ’excellent’ for
overall ease of dressing removal of 51% in the hydrocolloid dressing
group compared with 24% in the alginate dressing group but did
not report if the denominator was the number of participants or
the number of dressing changes (reported P value for between-
group difference 0.006). The percentage of dressing changes with
some adhesion to the wound bed was 38% in the hydrocolloid
dressing group compared with 74% in the alginate dressing group
(reported P value for between-group difference < 0.001).
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Adverse events
Smith 1994 reported that the number of participants who experi-
enced the adverse events of pain, allergy, wound infection or ery-
thema was 5/22 (23%) in the hydrocolloid dressing group com-
pared with 6/18 (33%) in the alginate dressing group. The be-
tween-group difference was not statistically significant (RR 1.47,
95% CI 0.53 to 4.03) (Analysis 2.5).
Armstrong 1997 reported 32 adverse events in the hydrocolloid
dressing group, four of which were attributed to the primary dress-
ing; 32 adverse events were recorded in the alginates dressing
group, with three attributed to the primary dressing. The number
of participants experiencing adverse events was not reported.
Hydrocolloid dressings compared with alginate dressings:
summary of results
Evidence from one RCT with an overall high risk of bias (Smith
1994), and two with unclear risk of bias (Armstrong 1997;
Harding 2001), suggested no difference between hydrocolloid and
alginate dressings for any healing outcomes (maximum follow-up
12 weeks). In terms of secondary outcomes, removal of hydrocol-
loid dressings was easier, whilst rates of adverse events appeared
to be similar between treatment groups. Findings were difficult
to interpret for exudate handling and pain (results were conflict-
ing), health-related quality of life (used unspecified measurement
instrument) and costs (no rigorously conducted economic eval-
uations reported). Interpretation of all secondary outcomes was
hampered further by lack of data in terms of variance estimates
and P values for tests of between-group differences. In addition,
findings were not always presented across all parts of the various
assessment scales used (e.g. pain, exudate handling and ease of
removal) and denominators were unclear for some dichotomous
outcomes - often because of ambiguity concerning whether the
rating was based on numbers of participants, or numbers of events
such as dressing changes.
Plain non-adherent dressings compared with alginate
dressings
We identified one RCT that compared plain non-adherent dress-
ings with alginate dressings; it had an overall high risk of bias
(Moffatt 1992).
Primary outcomes
Time to healing and proportion of ulcers completely healed
Moffatt 1992 randomised 60 participants: 30 received a plain non-
adherent dressing and 30 an alginate dressing. All participants
were fitted with a graduated compression bandaging system de-
signed to provide 40 mmHg ankle pressure; treatment duration
was 12 weeks. The number of ulcers healed at 12 weeks was 24/30
(80%) in the plain non-adherent dressing group compared with
26/30 (87%) in the alginate dressing group. The between-group
difference was not statistically significant (RR 1.08, 95% CI 0.86
to 1.36) (Analysis 3.1). Analyses relating to time to healing were
mentioned briefly, with trial authors stating that the cumulative
proportions healed (estimated from life table analysis) were simi-
lar to those in the above analysis. This could not be verified from
the trial report since no data or P value for the between-group
difference were presented.
Secondary outcomes
None reported.
Plain non-adherent dressings compared with alginate
dressings: summary of results
Evidence from one RCT, with an overall high risk of bias, sug-
gested no statistically significant difference between plain non-ad-
herent dressings compared with alginate dressings in the propor-
tion of ulcers completely healed at 12 weeks (Moffatt 1992). No
secondary outcomes were reported.
’Summary of findings’ tables
In order to provide a concise overview and synthesis of the vol-
ume and quality of the evidence, we have included a ’Summary of
findings’ table for each of the dressing comparisons: comparison
between different alginate dressings (Summary of findings for the
main comparison); alginate compared with hydrocolloid dressing
(Summary of findings 2); and alginate compared with non-adher-
ent dressing (Summary of findings 3). We had planned to include
estimates of time to healing, complete healing, change in wound
size, adverse events, and change in health-related quality of life in
the ’Summary of findings’ tables. Due to limitations of reported
data, we were only able to include estimates of complete healing
(for all comparisons) and adverse events (for alginate compared
with hydrocolloid). Data in the ’Summary of findings’ tables sug-
gest that the evidence for all comparisons is of very low quality,
meaning that there is much uncertainty around all estimates in-
cluded. On balance, there is no strong evidence of a benefit of
using alginate dressings compared with hydrocolloid or plain low-
adherent dressings for treating venous leg ulcers, and there is no
evidence to suggest that one brand of alginate dressing may be
better than another.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
alginate dressing compared to hydrocolloid dressing for venous leg ulceration
Patient or population: people with venous leg ulceration
Settings: outpatient clinics or community
Intervention: Alginate dressing
Comparison: hydrocolloid dressing
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Hydrocolloid dressing Alginate dressing
Time to healing See comment See comment Not estimable 0
(0)
See comment One RCT presented time
to healing, but did not re-
port a reliable estimate
(not based on censored
data)
Proportion of partici-
pants with healed ulcers
at 6 weeks
Follow-up: 6 weeks
Study population1 RR 0.42
(0.14 to 1.21)
84
(2 studies)
⊕©©©
very low2,3,4
233 per 1000 98 per 1000
(33 to 281)
Low1
91 per 1000 38 per 1000
(13 to 110)
High1
204 per 1000 86 per 1000
(29 to 247)
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Proportion of partici-
pants with healed ulcers
at 12 weeks
Follow-up: 12 weeks
Study population RR 1.02
(0.57 to 1.81)
131
(1 study)
⊕©©©
very low5,6,7,8
258 per 1000 263 per 1000
(147 to 466)
Low
311 per 1000 317 per 1000
(177 to 563)
High
696 per 1000 710 per 1000
(397 to 1000)
Mean change in wound
size, with adjustment for
baseline size
See comment See comment Not estimable 0
(0)
See comment Three RCTs reported
change in wound area,
but not with baseline ad-
justment
Proportion of partici-
pants experiencing ad-
verse effects at 6 weeks
Follow-up: 6 weeks
227 per 1000 334 per 1000
(120 to 916)
RR 1.47
(0.53 to 4.03)9
40
(1 study)
⊕©©©
very low10,11,12,13
Health-related quality of
life
See comment See comment Not estimable 0
(0)
See comment One RCT assessed
health-related quality of
life but did not use a
validated tool, and only
reported percentages of
participants who had im-
proved
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Note: lower risk of the outcome is less favourable (i.e. lower risk of healing) than higher risk. Estimates for baseline low and high risks
of healing at 30 days (and 90 days for the 12 week outcome) have been taken from a meta-analysis of RCTs evaluating different
types of compression. The low risk estimate is based on a subset of participants with larger baseline ulcer area (greater than 5 cm
squared). The high risk estimate is based on a subset of participants with smaller baseline ulcer surface area (5 cm squared or
smaller). Most participants received a simple, low-adherent dressing plus four-layer bandage (O’Meara 2007).
2 One RCT had overall unclear risk of bias and one had overall high risk of bias.
3 Underpowered comparison (N = 84).
4 Risk ratio estimate based on 2 RCTs; not possible to assess publication bias.
5 RCT had overall unclear risk of bias.
6 Risk ratio estimate based on single RCT; not possible to assess heterogeneity.
7 Underpowered comparison (N = 131).
8 Risk ratio estimate based on single RCT; not possible to assess publication bias.
9 Baseline event rate is taken from the control group in the RCT.
10 Estimate based on single RCT with overall high risk of bias.
11 Risk ratio estimate based on single RCT; not possible to assess heterogeneity.
12 Underpowered comparison (N = 40).
13 Risk ratio estimate based on single RCT; not possible to assess publication bias.
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alginate dressing compared to plain non-adherent dressing for venous leg ulceration
Patient or population: people with venous leg ulceration
Settings: community
Intervention: Alginate dressing
Comparison: plain non-adherent dressing
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Plain non-adherent
dressing
Alginate dressing
Time to healing See comment See comment Not estimable 0
(0)
See comment Assessment of time to
healing mentioned in RCT
report, but estimates not
provided
Proportion of partici-
pants with healed ulcers
Follow-up: 12 weeks
Study population1 RR 1.08
(0.86 to 1.36)
60
(1 study)
⊕©©©
very low2,3,4,5
800 per 1000 864 per 1000
(688 to 1000)
Low1
311 per 1000 336 per 1000
(267 to 423)
High1
696 per 1000 752 per 1000
(599 to 947)
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Mean change in wound
size, with adjustment for
baseline size
See comment See comment Not estimable 0
(0)
See comment Outcome not reported.
Adverse effects See comment See comment Not estimable 0
(0)
See comment Outcome not reported.
Health-related quality of
life
See comment See comment Not estimable 0
(0)
See comment Outcome not reported.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Note: lower risk of the outcome is less favourable (i.e. lower risk of healing) than higher risk. Estimates for baseline low and high
risks of healing at 90 days have been taken from a meta-analysis of compression RCTs. The low risk estimate is based on a subset
of participants with larger baseline ulcer surface area (greater than 5 cm squared). The high risk estimate is based on a subset of
participants with smaller baseline ulcer surface area (5 cm squared or smaller). Most participants received a simple, low-adherent
dressing plus four-layer bandage (O’Meara 2007).
2 RCT was at overall high risk of bias.
3 Risk ratio estimate based on single RCT; not possible to assess heterogeneity.
4 Underpowered comparison (N = 60).
5 Risk ratio estimate based on single RCT; not possible to assess publication bias.
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D I S C U S S I O N
Summary of main results
In this review we included five RCTs that recruited partici-
pants with venous leg ulceration (all identified during the origi-
nal review): one compared different proprietary alginate dressings
(Límová 2003), three compared alginate and hydrocolloid dress-
ings (Armstrong 1997;Harding 2001; Smith 1994), and one com-
pared alginate and plain non-adherent dressings (Moffatt 1992).
The primary outcome for the review was wound healing, which
could be reported as time to healing, proportion of participants
with complete healing, change in wound size and rate of heal-
ing. All the included RCTs assessed complete healing, three at six
weeks (Armstrong 1997; Límová 2003; Smith 1994), and two at
12 weeks (Harding 2001; Moffatt 1992). Reporting of other heal-
ing outcomes varied across RCTs. No statistically significant be-
tween-group differences were detected for any comparison for any
healing outcome. Meta-analysis was feasible for one comparison
(alginate and hydrocolloid dressings), with data from two RCTs
pooled for complete healing at six weeks: RR 0.42 (95% CI 0.14
to 1.21) (Analysis 2.1; Figure 4).
We included a range of secondary outcomes of potential impor-
tance in clinical decision making. These included costs, health-re-
lated quality of life, pain, debridement, haemostasis, dressing per-
formance (management of wound exudate and adherence to the
wound bed) and adverse events. Assessment and reporting varied
across RCTs; one RCT did not report any secondary outcomes
(Moffatt 1992), and there were no evaluations of haemostasis. In-
terpretation of data was often hindered because of poor reporting
of methods and findings. It is possible, however, that hydrocol-
loid dressings are better than alginate dressings for ease of dressing
removal, whereas adverse event profiles and dressing wear times
appeared to be similar between groups for the same comparison
(Armstrong 1997; Harding 2001; Smith 1994). The rationale for
the comparison between two proprietary alginate dressings (Tega-
gen ™ HG and Sorbsan®) was not stated, and the information
available suggests little difference between the two devices. How-
ever, Tegagen ™ HG appeared to be superior in terms of some
secondary outcomes (pain/comfort, exudate handling, ease of re-
moval and incidence of denuded peri-wound skin). The two dress-
ings appeared to be similar for other types of adverse effects (in-
cluding maceration) and debridement. These findings should be
viewed with caution because this RCT was very small (20 par-
ticipants) and so there is much uncertainty around the estimates
(Límová 2003).
Overall completeness and applicability of
evidence
Participant and intervention characteristics
With regard to confirmation of venous ulcer diagnosis, two
RCTs provided no information about methods of ascertainment
(Armstrong 1997; Smith 1994), one described using patient his-
tory and Doppler (Harding 2001), and the remaining two stated
a participant exclusion criterion of ABPI less than 0.8, but did
not describe methods of obtaining the measurement (Límová
2003; Moffatt 1992). Three RCTs mentioned presence of mod-
erate or high wound exudate as a participant inclusion criterion
(Armstrong 1997; Harding 2001; Límová 2003). Only one RCT
reported participant mobility, in which around half of the partic-
ipants had limited mobility or were immobile (Armstrong 1997).
Presence of ulcer infection was an exclusion criterion in two RCTs
(Límová 2003; Smith 1994), but was not mentioned in the re-
maining three RCTs (Armstrong 1997; Harding 2001; Moffatt
1992). The majority of RCTs imposed a limit to the baseline
wound size of 10 cm2 or less, to ensure that wound sizes would
not exceed the study dressing dimensions (Harding 2001). These
factors may limit applicability to clinical practice, where patients
with infected wounds - and a wide range of wound sizes - are
likely to be encountered. Imbalance of prognostic baseline co-
variates may have confounded the treatment effect in two RCTs,
both comparing alginate and hydrocolloid dressings: Armstrong
1997 reported participants having larger and more chronic ulcers
in the alginate group, whilst Smith 1994 indicated larger ulcers in
the hydrocolloid group (ulcer duration at baseline not reported).
No imbalances were apparent in two other RCTs (Límová 2003;
Moffatt 1992), and another did not present any data on ulcer area
or duration (Harding 2001).
All of the RCTs included reported the use of compression therapy
as part of the intervention, and we were unable to undertake our
planned subgroup analysis for the concurrent presence or absence
of compression. The type of compression therapy differed across
trials, and included orthopaedic padding covered by a high-com-
pression elastic bandage (Armstrong 1997; Harding 2001), paste
bandage plus an elastic cohesive bandage (Límová 2003), and an
unspecified bandage system designed to provide graduated com-
pression exerting 40 mmHg at the ankle (Moffatt 1992). The re-
maining RCT indicated the use of compression, but presented no
details about the specific device used (Smith 1994).
It is important to note that this review only identified evidence
on alginate dressings compared with alternative alginates, hydro-
colloids and non-adherent dressings: no comparisons were identi-
fied with other dressings, for example foam or hydrogel, therefore,
some potential data are lacking. In addition, the most recent of
the included RCTs was published in 2003 (Límová 2003), which
may limit the external validity of this review, if manufacturers have
made changes to alginate and comparator dressings in the interim
period. No new RCTs were identified during this first review up-
date.
Primary outcomes
Time to healing was assessed in only two of the five included RCTs
(Harding 2001; Moffatt 1992), one employed a log rank test to
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compare survival curves (Harding 2001), and the other analysed
this outcome by life table (Moffatt 1992). However, whilst both
RCTs suggested that the results for time to healing were similar
across groups, Moffatt 1992 reported no outcome data by group,
and neither RCT reported the associated P value. One of these
RCTs also evaluated this outcome as a mean time to healing (
Harding 2001). This analysis approach would only account for
those participants whose ulcers healed. Participants whose ulcers
did not heal during the trial (censored data) would not have been
accounted for by this analysis method, which could result in a
biased effect estimate (Deeks 2011). The limited way in which
this outcome was analysed and reported impedes any inference
regarding the efficacy of alginate dressings in terms of time to
healing.
All included RCTs reported the proportion of ulcers healed, en-
abling us to estimate between-group differences. The comparison
between hydrocolloid dressings and alginate dressings comprised
three RCTs (Armstrong 1997; Harding 2001; Smith 1994). For
the other two comparisons, estimates were based on a single RCT:
Tegagen™HG versus Sorbsab alginate dressings (Límová 2003);
and alginate versus plain non-adherent dressings (Moffatt 1992).
The follow-up period was short in all included RCTs (six or 12
weeks).
Four RCTs reported change in wound size; interpretation of this
outcome was often hampered by incomplete presentation of data
(i.e. lack of variance estimates or P values, or both) (Armstrong
1997; Límová 2003; Smith 1994). One RCT provided sufficient
information on absolute and percentage area changes for us to
calculate mean differences with associated 95% CIs (Harding
2001). None of the included RCTs reported rate of healing over
time.
Secondary outcomes
One RCT reported a health-related quality of life assessment, but
did not clarify the number of participants on which it was based,
and presented only the proportion that had achieved the most
favourable outcome category of its five-point scale (Smith 1994).
The scale used was an unspecified instrument that was unlikely
to be valid and reliable. Whilst outcomes appeared to be similar
between groups, no variance estimates or P value for the between-
group differences were reported.
One RCT reported mean cost to heal one ulcer (material costs
and nursing costs), but lacked the necessary variance data to esti-
mate a between-group difference (Harding 2001). The same RCT
reported mean wear time with a variance estimate, and we were
able to calculate a between-group difference that indicated no sta-
tistically significant difference between alginate and hydrocolloid
dressings.
Across the RCTs that reported pain as an outcome, the mode and
timing of the assessment was very varied, as was the reporting of
data. Estimation of difference in means was feasible for one small
RCT (Límová 2003), that indicated that Tegagen™HG alginate
dressing was statistically significantly better than Sorbsan® algi-
nate dressing in terms of comfort during wear time and dressing
removal.
One RCT reported the percentage of visits at which debridement
was required and where necrotic tissue was observed, but did not
report the numbers of participants concerned (Límová 2003).
Haemostasis was not reported by any of the included RCTs.
The included RCTs assessed and reported dressing performance
(exudate management and ease of removal/adherence to the
wound bed) in a variety of ways. These outcomes were often as-
sessed subjectively and were sometimes reported as count data.
Estimation of difference in means was undertaken for one small
RCT (Límová 2003), that suggested that Tegagen™HG alginate
dressing was statistically significantly better than Sorbsan® algi-
nate dressing in terms of exudate absorption and ease of dressing
removal.
The reporting of adverse events across the three RCTs that assessed
this outcomewas disparate (Armstrong 1997; Límová 2003; Smith
1994). In two RCTs it was unclear how many participants expe-
rienced adverse events because the denominators were events and
assessments (Armstrong 1997; Límová 2003, respectively). Only
one report of this outcome permitted an assessment of between-
group difference, which indicated no statistically significant differ-
ence between alginate and hydrocolloid dressings (Smith 1994).
Cautious interpretation of secondary outcome data is required
because of the subjective nature of many of the assessments. Most
of the scales used appear to have been designed solely for the use
of the trial and were unlikely to have been demonstrated to be
valid and reliable instruments. In addition, poor reporting was
common with a lack of data for variance estimates, P values for
between group differences, and failure to present the complete set
of data for some assessment scales (in some cases only the most
favourable outcome category was presented).
Quality of the evidence
Two of the five included RCTs were considered to be at overall
high risk of bias, one because some randomised participants had
not been accounted for in the analysis (Smith 1994), and the
other because the outcome assessment was not blinded (Moffatt
1992). Missing outcome data, due to attrition (drop-out) during
the trial or exclusion of participants from the analysis, can bias the
effect estimate, and lack of blinding of participants or healthcare
providers can bias the results by influencing outcomes (Higgins
2011). The other three RCTs were classified as having an unclear
overall risk of bias (Armstrong 1997; Harding 2001; Límová
2003).
All five included RCTs were published prior to the current CON-
SORT (Consolidated Standards of Reporting Trials) guidelines
(Schulz 2010). Key aspects of best practice in RCT design to min-
imise bias include a robust randomisation method, concealment
of treatment group allocation, blinding of participants and trial
personnel, and blinded outcome assessment, all of which should
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be clearly stated in the RCT report. None of the included RCTs
in this review reported the method of generation of the random
sequence, or an adequate method of allocation concealment, and
there was evidence of selective outcome reporting in four of the
five included RCTs.
The ’Summary of findings’ tables indicate that the current evidence
base for the effects of alginate dressings compared with alternatives
on the healing of venous leg ulcers is of very low quality (Summary
of findings for the main comparison; Summary of findings 2;
Summary of findings 3).
Potential biases in the review process
In addition to the electronic searches of bibliographic databases,
the search for evidence for the original review and this first update
included: examination of reference lists of eligible RCTs and re-
view articles; contact with trial authors; and ongoing trials regis-
ters. During the original review we also contacted manufacturers
of alginate dressings. Although this search strategy was compre-
hensive, the possibility of publication bias cannot be discounted.
However, given the lowquality of theRCTs identified for inclusion
(all were published reports), coupled with the absence of any ob-
served statistically significant treatment effects on ulcer healing, it
is unlikely that any additional unpublished data would contribute
substantially to the overall findings of this review.
Agreements and disagreements with other
studies or reviews
The evidence base to guide dressing choice suggests that there
is no evidence to support alginate dressings as being better or
worse than other dressing treatments for the healing of venous
leg ulcers. This observation is in agreement with the Palfreyman
2007 systematic review, which reported that there was insufficient
data available to conclude that any one dressing type was more
effective than any other in healing venous leg ulcers. There is some
overlap between our review and the Palfreyman 2007 review, with
three RCTs common to both (Límová 2003; Moffatt 1992; Smith
1994).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
At present, there is no evidence to suggest any differences in terms
of wound healing between different alginate dressings, or between
alginate dressings and hydrocolloid dressings, or alginate dress-
ings and non-adherent dressings. It is possible that dressing per-
formance, in terms of ease of removal, is better for hydrocolloid
dressings than alginate dressings. Adverse event profiles were gen-
erally similar between treatment groups (not assessed for alginate
versus plain non-adherent dressings).
The current evidence base is of low quality. The lack of good
quality evidence limits any specific recommendations regarding
the use of any of the dressing types reviewed here for the healing
of venous leg ulcers. Further, good quality evidence is required
fromwell designed randomised controlled trials (RCTs) before any
definitive conclusions regarding the efficacy of alginate dressings
in the management of venous leg ulcers can be drawn.
Implications for research
All of the RCTs included in this review have methodological and
reporting problems. Future RCTs that compare wound dressings
should employ robust randomisation methods and concealment
of allocation procedures to minimise bias. In addition, blinded
outcome assessment and use of the intention-to-treat principle for
data analysis should be adopted in order to minimise bias. These
methodological aspects should be reported clearly, in line with the
CONSORT (Consolidated Standards of Reporting Trials) guide-
lines (Schulz 2010). Assessment of time to healing should be mea-
sured and reported using appropriate survival analysis with adjust-
ment for prognostic covariates such as ulcer area and duration. Fu-
ture RCTs should be adequately powered in order to detect treat-
ment effects, and estimations that guide decisions regarding sam-
ple size should be reported clearly. Those planning future RCTs
should consider the extent to which the recruited population is
likely to represent patients seen in clinical practice, particularly
with respect to mobility, ulcer size and duration, and the presence
of ulcer infection.
Further research is required to investigate the safety and tolerability
of wound dressings for venous leg ulcers. Health-related quality
of life assessment should be undertaken using a valid and reliable
assessment instrument, with findings reported in full. As dressing
choice for the management of venous leg ulcers may be guided by
cost, those planning future RCTs should consider incorporation
of meaningful cost-effectiveness information.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Armstrong 1997
Methods Design: open, multicenter RCT - 3 centres
Country: UK (2 centres) and France (1 centre)
Setting: centres specialising in the treatment of leg ulceration
Sample size calculation: not reported
Ethical approval: not reported
Informed consent: not reported
Participants 44patients recruited fromcentres specialising in the treatment of leg ulceration. Inclusion
criteria: males and females over 18 years of age presenting with an ulcer of any aetiology
≤ 7.5 cm in diameter, producing moderate to heavy amounts of exudate. Exclusion
criteria: none specified
Numbers randomised:
Group 1 (hydrocolloid dressing): 21 participants
Group 2 (alginate dressing): 23 participants
Mean participant age:
Group 1 (hydrocolloid dressing): 71 years (SD 10)
Group 2 (alginate dressing): 65 years (SD 11)
Number male:
Group 1 (hydrocolloid dressing): 10/21 (48%)
Group 2 (alginate dressing): 13/23 (57%)
Number of participants with ulcers of venous, mixed or other aetiology:
Group 1 (hydrocolloid dressing): 17/21 (81%), 3/21 (14%), 1/21 (5%)
Group 2 (alginate dressing): 19/23 (83%), 3/23 (13%), 1/23 (4%)
ABPI: not reported
Unit of analysis: Participant
Number of participants who had limited mobility or were immobile:
Group 1 (hydrocolloid dressing): 13/21 (62%)
Group 2 (alginate dressing): 11/23 (48%)
Baseline ulcer area mm2 - median (range):
Group 1 (hydrocolloid dressing): 491 (64-2081)
Group 2 (alginate dressing): 611 (60-1830)
Baseline ulcer duration months - median (range):
Group 1 (hydrocolloid dressing): 9 (1-47)
Group 2 (alginate dressing): 12 (1-120)
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Armstrong 1997 (Continued)
Ulcer infection: not reported
Participant ulcer history: not reported
Number of participants with heavily exuding ulcers:
Group 1 (hydrocolloid dressing): 1/21 (5%)
Group 2 (alginate dressing): 5/23 (22%)
Comments: a moderately-exuding wound was defined as one requiring a dressing change
every seconddaywith a conventional dressing (tulle), or every third daywith an absorbent
dressing. A heavily-exuding wound was defined as needing a dressing change daily, or
more frequently, with a conventional dressing, or every second day with amore absorbent
dressing
The trial authors reported that there was an imbalance as participants in Group 1 had
ulcers which were smaller and of shorter duration at baseline
Interventions Group 1: hydrocolloid-fibrous dressing (Aquacel, manufacturer not reported)
Group 2: alginate dressing (Kaltostat, ConvaTec)
The dressing was changed if there had been leakage, if infection was suspected, if a
participant complained of pain, or once it had been in place for 7 days. A standardised
secondary dressing and bandaging regimen applied over the primary dressing consisted
of an occlusive hydrocolloid (DuoDerm Extra Thin) as the secondary dressing and, if
indicated, orthopaedic padding and a Class 3C compression bandage (Tensopress)
Description of compression therapy: Class 3C compression bandage (Tensopress)
Length of treatment: 6 weeks, or until healing if sooner
Follow-up: 6 weeks
Outcomes Review-relevant outcomes:
Time to healing: not reported.
Proportion of ulcers healed: reported, photography and planimetry used to measure the
wound on enrolment, on days 14 and 28, and on completion of the trial period
Change in ulcer size: reported.
Healing rate: not reported.
Quality of life: not reported.
Costs: reported, direct costs (primary dressings, compression treatment and saline wound
cleanser) and indirect costs (nurse time, calculated at GBP 2.03 per dressing change)
measured. Costs based on 1995 Drug Tariff prices and manufacturer’s costs for the
hydrocolloid dressing.Total dressing cost was calculated per participant. Mean cost to
achieve a healed ulcer was calculated by treatment group. Mean wear time was estimated
from the first to last dressing change
Pain: reported, pain on dressing removal assessed on a scale of 0-5 (0 = none, 1 = mild,
2 = moderate, 3 = severe, 4 = excruciating, 5 = unable to respond)
Debridement: not reported.
Haemostasis: not reported.
Dressing performance - exudate handling: secondary referencementions ’noting leakage’,
but exudate levels not reported in the results
Dressing performance - adherence/sticking: secondary reference mentions ’ease of re-
moval’, but not reported in the results
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Armstrong 1997 (Continued)
Adverse events: reported, safety monitored by documenting all adverse events
Other outcomes assessed by the trial: none reported.
Notes Sponsor: ConvaTec Ltd (trial number not reported)
Number participants withdrawing and reasons:
Group 1 (hydrocolloid dressing): 5/21 (24%) participant request, 1; adverse events, 4
Group 2 (alginate dressing): 7/23 (30%) all due to adverse events
Adverse events that prompted withdrawal described as: bleeding; increased erythema;
and deterioration of the ulcer (not reported by group)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Twenty-one patients were ran-
domized to the Hydrocolloid dressing and
23 to the alginate.” (Armstrong 1996)
Comment: sequence generation method
not reported
Allocation concealment (selection bias) Unclear risk Quote: “Subjects were then randomized to
the primary dressings under investigation
by the use of sealed envelopes opened in a
numerical order.”
Comment: no statements about whether
the envelopes were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “An open, comparative, random-
ized, multi-centre trial design was adopted.
” (Armstrong 1996)
Comment: no statement regarding blind-
ing of participants or study personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “An open, comparative, random-
ized, multi-centre trial design was adopted.
” (Armstrong 1996)
Comment: no statement regarding blinded
outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Data were analysed on an inten-
tion-to-treat basis.”
Selective reporting (reporting bias) High risk Comment: the reported outcome of pro-
portion of participants achieving a 7-day
wear time was not mentioned in the meth-
ods section. Two outcomes in the sec-
ondary reference (exudate handling ability
of the dressing and ease of removal) were
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Armstrong 1997 (Continued)
not reported. Trial protocol not available
(email communication with trial sponsor)
Harding 2001
Methods Design: open, multicenter RCT - 4 centres
Country: UK (4 centres)
Setting: community
Sample size calculation: a sample size of 90 evaluable participants (i.e. either completed
the 12 week trial or healed) estimated as having 80% power to detect between-group
difference in mean wear time of 1 day at 5% significance, assuming a SD of 1.7 days
Ethical approval: ethical approval was granted from the relevant local ethics committees
Informed consent: participants were recruited once written informed consent was ob-
tained
Participants Recruited 131 participants with moderately- to heavily-exuding leg ulcers
Inclusion criteria: people with moderately- to heavily-exuding leg ulcers of varying aeti-
ology, provided they were suitable for treatment with either dressing. Wound aetiology
assessed using patient history and Doppler
Exclusion criteria: people who had been in the trial previously and those with: a known
history of poor compliance with treatments, wounds too large for the dressings, or dry
eschar on the wound
Numbers randomised:
Group 1 (hydrocolloid dressing): 66 participants
Group 2 (alginate dressing): 65 participants
Mean participant age (range):
Group 1 (hydrocolloid dressing): 75.53 years (35-93)
Group 2 (alginate dressing): 77.6 years (43-97)
Number male:
Group 1 (hydrocolloid dressing): 21/66 (32%)
Group 2 (alginate dressing): 12/65 (18%)
Number participants with ulcers of venous, mixed, arterial or diabetic aetiology:
Group 1 (hydrocolloid dressing): 54/66 (82%), 9/66 (13%), 2/66 (3%), 1/66 (2%)
Group 2 (alginate dressing): 49/65 (75%), 6/65 (10%), 9/65 (13%), 1/66 (2%)
ABPI: not reported
Unit of analysis: participant
Participant mobility: not reported
Baseline ulcer area: not reported
Exclusion criteria included wounds that were too large for the dressings. Dressings used
were 5 cm x 5 cm and 10 cm x 10 cm
Baseline ulcer duration: not reported
Ulcer infection: not reported
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Harding 2001 (Continued)
Participant ulcer history: not reported
Participant baseline exudate levels: not reported
Comments: trial authors reported that participantswerewellmatched in terms of baseline
wound characteristics, but no data were reported
Interventions Group 1: hydrocolloid fibre dressing (Aquacel, ConvaTec)
Group 2: alginate dressing (Sorbsan®, Maersk)
Both dressings available in 5 cm x 5 cm and 10 cm x 10 cm sizes. Both groups received
an absorbant pad as a secondary dressing (Release, Johnson & Johnson). Dressings could
be left in place for up to 7 days (according to manufacturers’ instructions) and were
changed according to clinical need. If the wound became infected, dressings in Group 2
were changed daily (manufacturers’ instructions). If the wound became infected during
the trial, systemic antibiotics were prescribed and the participant remained in the trial. If
topical antibiotic treatment was required, the participant was withdrawn from the trial
Description of compression therapy: where clinically indicated, compression provided
using orthopaedic padding and a Class 3C elastic bandage (SurePress, ConvaTec)
Length of treatment: 12 weeks, or until healing
Follow-up: participants were followed up until they healed, or for a maximum of 12
weeks
Outcomes Review relevant outcomes reported:
Time to healing: reported, wound size assessed using acetate tracings.Wound assessments
performed on a weekly basis. Analysed using log rank test to compare Kaplan-Meier
survival curves
Proportion of ulcers healed: reported
Change in ulcer size: reported
Healing rate: not reported
Quality of life: not reported
Costs: reported, cost -effectiveness calculated by comparing clinical costs with costs in
the International Committee on Wound Management and the Health economic UK
Guidelines. All materials used at each dressing change were used to estimate mean costs.
Included an additional GBP 15 (USD 21.53) at each dressing change to reflect cost of
nursing staff. Costs calculated using May 2000 Drug Tariff prices (with the exception of
the orthopaedic wool). Estimated a mean cost associated with a 1 cm2 reduction and a
10% reduction in ulcer area per treatment group, and the mean cost of a healed ulcer
Pain: reported, pain on dressing removal was assessed by participant self-reporting on a
four-point scale (’no pain’ to ’severe pain’). Also, pain on dressing removal was assessed
by the participant on a “yes/no” basis
Debridement: not reported
Haemostasis: not reported
Dressing performance - exudate handling: reported, assessed by investigator using 4-
point scale ranging from “poor” to “excellent” on a patient-by-patient basis
Dressing performance - adherence/sticking: reported, assessed by investigator using 4-
point scale ranging from “poor” to “excellent” on a patient-by-patient basis. Also, at each
dressing change dressings were assessed for adhesion on a “yes/no” basis
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Harding 2001 (Continued)
Adverse events: not reported
Other outcomes assessed by the trial: ease of application and residue observed on dressing
change
Review authors’ comment: the trial authors stated that ease of dressing removal, exudate
handling and level of pain on dressing removal were assessed by both the investigator
and participant
Notes Sponsor: ConvaTec (trial number not reported)
Participant withdrawal: trial authors did not report on participant withdrawal in the
primary reference. Secondary reference reported a larger sample size described as “mainly
community based”. Possibility that primary reference only reported on the community-
based participants (not stated)
Number participantswithdrawingbased on review authors’ comparison betweenprimary
and secondary references:
Group 1 (hydrocolloid dressing): 1/67 (1.5%)
Group 2 (alginate dressing): 4/69 (6%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients were randomized to one
of the following dressings:”
Comment: sequence generation method
not reported
Allocation concealment (selection bias) Unclear risk Quote: “Randomization to study treat-
ment using sealed envelopes was made at
this point and the patients’ wounds dressed
accordingly, . . . ”
Comment: no statement that envelopes
were opaque and sequentially numbered
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “This paper reports the results of an
open, prospective, randomized, controlled,
multicenter evaluation . . .”
Comment: no statement regarding blind-
ing of participants or study personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “Both the investigator and patient
measured the secondary outcomes”
Comment: no statement regarding blinded
outcome assessment of primary outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Data were processed on an ’inten-
tion to treat’ basis so that all information
relating to a subject who participated in the
39Alginate dressings for venous leg ulcers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Harding 2001 (Continued)
study was retained
Selective reporting (reporting bias) High risk Quote: ”Both the investigator and patient
measured the secondary outcomes.”
Comment: only one set of results was pre-
sented for the secondary outcomes and it
was not reported whether these were as-
sessed by the participants or investigators
Quote: “Overall ease of application and re-
moval was assessed by the investigator us-
ing a four-point scale ranging from ‘poor’
to ‘excellent’ on a patient-by-patient basis.
”
Comment: results were not presented for
the full 4-point scale for ease of application
- only the proportion recorded as “excel-
lent” was reported
Límová 2003
Methods Design: open RCT
Country: USA (2 centres)
Setting: outpatients
Sample size calculation: not reported
Ethical approval: not reported
Informed consent: one of the inclusion criteria was that participants should be willing
to sign informed consent before enrolment
Participants Recruited 20 people from wound clinics.
Inclusion criteria: outpatients≥ 21 years, able to understand the product application and
assessment procedures, and willing to sign informed consent. Required to have a venous
insufficiency ulcer of at least 1month duration, with area 3 cm2 to 100 cm2 andmoderate
(3-5 ml) to large amount (> 5 ml) of exudate. Initial assessment included recording ulcer
history and determination of ulcer status (stable, improving or worsening)
Exclusion criteria: ABPI < 0.8, uncontrolled diabetes, underlying vasculitis, on immuno-
suppressive therapy, ulcer showing signs of infection, presence of pre-existing local skin
disease or condition that could affect trial results, or an allergy to the trial materials
Numbers randomised:
Group 1 (alginate dressing, Tegagen ™ HG): 11 participants
Group 2 (alginate dressing, Sorbsan®): 9 participants
Baseline data were reported for participants completing the trial:
Group 1 (Tegagen ™ HG): 10 participants
Group 2 (Sorbsan®): 9 participants
Participant age - mean (range):
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Límová 2003 (Continued)
Group 1 (alginate dressing, Tegagen ™ HG): 75.4 years (51-88)
Group 2 (alginate dressing, Sorbsan®): 72.1 years (45-93)
Number male:
Group 1 (alginate dressing, Tegagen ™ HG): 3/10 (30%)
Group 2 (alginate dressing, Sorbsan®): 0/9 (0%)
ABPI: ABPI < 0.8 amongst exclusion criteria. No data reported by group
Unit of analysis: participant
Participant mobility: not reported
Baseline ulcer area cm2 - mean (range):
Group 1 (alginate dressing, Tegagen ™ HG): 6.9 (1.0-16.8)
Group 2 (alginate dressing, Sorbsan®): 8.5 (1.6-21.7)
Baseline ulcer duration - mean (range):
Group 1 (alginate dressing, Tegagen ™ HG): 6.1 months (2-14)
Group 2 (alginate dressing, Sorbsan®): 9.1 months (1-24)
Participant ulcer history: not reported
Number of ulcers categorised asworsening, stable, improving (exact nature of this variable
unclear from RCT report):
Group 1 (alginate dressing, Tegagen ™ HG): 4/10 (40%), 6/10 (60%), 0/10 (0%)
Group 2 (alginate dressing, Sorbsan®): 7/9 (77.8%), 2/9 (22.2%), 0/9 (0%)
Ulcer infection: participants with ulcers showing signs of infection were excluded
Number of participants with ulcers with foul odour:
Group 1 (alginate dressing, Tegagen ™ HG): 1/10 (10.0%)
Group 2 (alginate dressing, Sorbsan®): 2/9 (22.2%)
Number participants with medium to large amounts of exudate:
Group 1 (alginate dressing, Tegagen ™ HG): 10/10 (100%)
Group 2 (alginate dressing, Sorbsan®): 9/9 (100%)
Breakdown by medium and large levels of exudate not reported
Number of participants with purulent serosanguineous exudate:
Group 1 (alginate dressing, Tegagen ™ HG): 3/10 (30%)
Group 2 (alginate dressing, Sorbsan®): 6/9 (66.7%)
Number of participants with macerated peri-wound skin:
Group 1 (alginate dressing, Tegagen ™ HG): 5/10 (50%)
Group 2 (alginate dressing, Sorbsan®): 4/9 (44.4%)
Number of participants with necrotic tissue:
Group 1 (alginate dressing, Tegagen ™ HG): 10/10 (100%)
Group 2 (alginate dressing, Sorbsan®): 9/9 (100%)
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Límová 2003 (Continued)
Number of participants with ulcers that required debridement:
Group 1 (alginate dressing, Tegagen ™ HG): 7/10 (70%)
Group 2 (alginate dressing, Sorbsan®): 3/9 (33.3%)
Comment: recruited some participants with ulcers smaller than those described as eligible
for inclusion
Interventions Group 1: alginate dressing (Tegagen ™ HG (High Gelling),3M)
Group 2: alginate dressing (Sorbsan®, Dow Hickman)
Need for debridement (surgical debridement not requiring anaesthesia) of fibrin or
necrotic tissue from wounds assessed at weekly dressing changes. Dressing changes com-
pleted weekly. The secondary dressing (Tegasorb hydrocolloid dressing, 3M) the same
for both groups. Applied 3M Cavilon No Sting Barrier Film (3M) if peri-wound skin
was denuded or macerated
Description of compression therapy:
Medicopaste Bandage (Graham-Field) and 3M Coban Self-Adhesive Wrap (3M)
Length of treatment: 6 weeks, or until ulcer no longer required the use of an alginate
dressing
Follow-up: participants followed up for a maximum of 6 weeks, or until the venous leg
ulcer no longer required the use of a calcium alginate dressing
Outcomes Review-relevant outcomes reported:
Time to healing: not reported
Proportion of ulcers healed: reported, wounds assessed weekly using a wound tracing
and a photograph
Change in ulcer size: reported
Healing rate: not reported
Quality of life: not reported
Costs: reported, recorded the number of dressing changes over the course of the trial
Pain: reported, comfort during dressing wear and at removal assessed by asking partici-
pants if they experienced itching, pain, or other problems. Dressings rated on a scale of
1 (very good) to 5 (very poor)
Debridement: reported, recorded the percentage of visits where necrotic tissue was ob-
served and debridement required. The amount of necrotic tissue was graded as 0 = none,
1 = ≤25%, 2 = 26%-50%, 3 = 51%-75%, 4 = 76%-99%, 5 = 100%
Haemostasis: not reported
Dressing performance - exudate handling: reported, estimated by observation of the
wound and dressing at dressing removal (dry wound; small amount, 1-2 ml exudate;
medium amount, 3-5ml exudate; large, > 5ml exudate). Dressings rated on scale ranging
from 1 (very good) to 5 (very poor) in terms of exudate absorption
Dressing performance - ease of removal: reported, rated during weekly assessment visits
on a scale ranging from 1 (very good) to 5 (very poor). Dressing adherence to wound
bed rated as ’yes’ or ’no’
Adverse events: reported, peri-wound skin condition classified as normal, denuded, mac-
erated, or flaky/dry. Reported whether peri-wound skin required medication
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Límová 2003 (Continued)
Other outcomes assessed by the trial: condition of the wound edge; type and amount
of necrotic tissue; amount of granular tissue and epithelialisation; dressing comfort; ease
of application; conformability of dressing to the site; itching or other problems; and
dressing residue on wound bed
Notes Sponsor: a ’company sponsor’ is mentioned as having provided training to evaluators,
but name not provided
Number of participants withdrawing and reasons:
Group 1 (alginate dressing, Tegagen ™ HG): 1/11(9%), left after 1 week due to an
unrelated adverse event
Group 2 (alginate dressing, Sorbsan®): no details regarding participant withdrawal re-
ported, assume 0/9 (0)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Patients provided informed con-
sent and were randomized to one of the
treatment groups according to the protocol
randomization schedule.”
Comment: sequence generation method
not reported
Allocation concealment (selection bias) Unclear risk Comment: allocationmethod not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “The purpose of this open, ran-
domized, controlled clinical study was to
compare the performance characteristics
and clinical effect of two calcium alginate
dressings in the management of venous leg
ulcers:”
Comment: no statement regarding blind-
ing of participants or study personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “All wound assessments and dress-
ing performance evaluations were under-
taken by either the primary investigator or
her designate (RN staff member).”
Comment: no statement regarding blind-
ing of the outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “One patient in the Alginate A
group (Group 1) left the study after 1 week
due to an unrelated adverse event and was
not included in the analyses.”
Comment: reason for drop-out stated as
unrelated to treatment (although nature of
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Límová 2003 (Continued)
the adverse event not reported)
Selective reporting (reporting bias) Low risk Comment: outcomes described in the
methods section matched those reported in
the results section
Unable to obtain trial protocol
Moffatt 1992
Methods Design: RCT (pilot study)
Country: UK
Setting: community
Sample size calculation: not reported, trial was a pilot study
Ethical approval and informed consent: trial authors described methods used in the
discussion section of the paper, and indicated that ethical approval and informed consent
were both obtained
Participants Recruited 60 patients from the community
Inclusion criteria: people with ulcers < 10 cm2. All participants had ABPI measurements
Exclusion criteria: ABPI < 0.8
Numbers randomised:
Group 1 (plain non-adherent dressing): 30 participants
Group 2 (alginate dressing): 30 participants
Median participant age (range):
Group 1 (plain non-adherent dressing): 70 years (38-88)
Group 2 (alginate dressing): 78 years (44-88)
Number of males:
Group 1 (plain non-adherent dressing): 13/30 (43%)
Group 2 (alginate dressing): 10/30 (33%)
ABPI: ABPI < 0.8 an exclusion criterion. No data reported by group
Unit of analysis: participant
Participant mobility: not reported
Baseline ulcer size - median (range):
Group 1 (Plain non-adherent dressing): 6.4 (1.1-9.9)
Group 2 (alginate dressing): 3.6 (0.9-9.8)
Unit of measurement not stated, assume cm2
Baseline ulcer duration, unit ofmeasurement not stated, assumemonths -median (range)
:
Group 1 (plain non-adherent dressing): 3 (1-20)
Group 2 (alginate dressing): 2 (1-192)
Ulcer infection: not reported
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Participant ulcer history: not reported
Participant baseline exudate levels: not reported
Interventions Group 1: plain non-adherent dressing (proprietary name not reported, Johnson and
Johnson)
Group 2: alginate dressing (Tegagel, 3M)
Weekly cleaning and re-dressing of ulcers unless excessive exudate or infection occurred,
in which case dressing and bandage changes were more frequent
Description of compression therapy:
All participants fitted with a graduated compression bandaging system to produce and
sustain 40 mmHg at the ankle (exact device not specified)
Length of treatment: 12 weeks
Follow-up: 12 weeks
Outcomes Review-relevant outcomes reported:
Time to healing: reported, healing assessment method not described. Data analysis was
by life table, with comparison between-groups by the log rank method
Proportion of ulcers healed: reported
Change in ulcer size: not reported
Healing rate: not reported
Quality of life: not reported
Costs: not reported
Pain: not reported
Debridement: not reported
Haemostasis: not reported
Dressing performance - exudate handling: not reported
Dressing performance - adherence/sticking: not reported
Adverse events: not reported
Other outcomes assessed by the trial: none reported.
Notes Sponsor: 3M Health Care Ltd (trial number not reported)
Number of participants withdrawing and reasons: trial authors did not report on partic-
ipant withdrawal
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Following assessment for arterial
disease, patients were entered into the trial
and randomised to either of the two dress-
ing types.”
Comment: sequence generation method
not reported
Allocation concealment (selection bias) Unclear risk Comment: allocationmethod not reported
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Moffatt 1992 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: no statement regarding blind-
ing of participants or study personnel
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “One of the difficulties of running
trials of this nature is that the person assess-
ing efficacy cannot be ‘blind’ to the treat-
ment that is being offered to the patient.”
Comment: trial authors described the
methods used in the discussion, and in-
dicated that outcome assessment was not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Analysis based on ’intention to
treat’ is a standard method.”
Comment: trial authors described the
methods used in the discussion, and indi-
cated that ITT was undertaken
Selective reporting (reporting bias) High risk Quote: “Data analysis was by life table for
time to healing, with comparison between-
groups by the log rank method.”
Comment: trial authors described the
methods used to assess time to healing, but
no results data presented
Smith 1994
Methods Design: open RCT
Country: UK
Setting: hospital dermatology department
Sample size calculation: not reported
Ethical approval: not reported
Informed consent: recruited consenting adults
Participants Recruited 40 people from a hospital dermatology department
Inclusion criteria: people with a venous leg ulcer > 2.5 cm in diameter
Exclusion criteria: any condition that might affect wound healing (infection, immune
deficiency, treatment with steroids, malignant disease), ulcer not clearly of venous origin,
systemic treatment that might affect ulcer healing (fibrinolytic or anticoagulant therapy)
, or if other treatment was deemed better
Numbers randomised:
Group 1 (hydrocolloid dressing): 22 participants
Group 2 (alginate dressing): 18 participants
Baseline participant age, % male, and mobility:
The trial authors reported that there were no statistically significant differences at baseline
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Smith 1994 (Continued)
in participants in terms of sex, age or mobility. No data were reported
ABPI: not reported
Unit of analysis: participant
Baseline ulcer area cm2 - mean:
Group 1 (hydrocolloid dressing): 22.17
Group 2 (alginate dressing): 12.74
Baseline ulcer size, ulcer duration, and participant ulcer history: not reported
Baseline ulcer infection: presence of infection was an exclusion criterion
Mean ulcer pain score at baseline (during previous 2weeks, lower score better):
Group 1 (hydrocolloid dressing): 4.74
Group 2 (alginate dressing): 4.86
Participant baseline exudate levels: not reported
Comments: trial authors commented that the mean ulcer size at enrolment was consid-
erably larger in Group 1
Interventions Group 1: hydrocolloid dressing: (Improved Formulation Granuflex, ConvaTec)
Group 2: alginate dressing (type and manufacturer not reported)
Wounds cleaned with physiological saline and dressings applied according to manufac-
turers’ instructions. Participants re-attended dermatology clinic for ulcer dressing when-
ever necessary
Description of compression therapy:
Compression bandaging applied to each participant, but details of type not reported
Length of treatment: 6 weeks
Follow-up: trial dressing continued for 6 weeks, or until the ulcer healed
Outcomes Review relevant outcomes reported:
Time to healing: not reported
Proportion of ulcers healed: reported, an acetate tracing of the ulcer made on the first
and last day of the trial, and the ulcer area calculated using an image analyser
Change in ulcer size: reported
Healing rate: not reported
Quality of life: reported, assessed over the previous 2 weeks at weeks 0, 2, 4 and 6 on
a 5-point scale (deteriorated markedly, deteriorated somewhat, no change, improved
somewhat or improved markedly). Name of scale not provided and no mention of using
a validated instrument to assess health-related quality of life
Costs: reported, completed a costing sheet, listing all materials used, at each dressing
change. Nursing time not included and price year/tariff not provided. Frequency of
dressing changes assessed as the mean number of changes over 2 weeks Assessment of
wear time mentioned, but no details of assessment provided
Pain: reported, pain was assessed over the previous 2 weeks at weeks 2, 4, and 6 using
a 10-point visual analogue scale (0 = no pain to 10 = worse pain). Pain that disturbed
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Smith 1994 (Continued)
sleep assessed (as: often, sometimes, rarely) and also pain at dressing change (10-point
VAS as before)
Debridement: not reported
Haemostasis: not reported.
Dressing performance - exudate handling: reported, the ability of dressings to contain
exudate rated on a 6-point scale (excellent, very good, good, fair, poor or awful)
Dressing performance - adherence/sticking: reported, ease of removal assessed on a 6-
point scale (excellent, very good, good, fair, poor, awful)
Adverse events: reported, all adverse events recorded, including severe pain and suspected
infection of the ulcer
Other outcomes assessed by the trial: convenience of dressing changes; participant com-
fort; ease of application
Notes Sponsor: ConvaTec Ltd (trial number not reported)
Number of participants withdrawing and reasons:
Group 1 (hydrocolloid dressing): 6/22 (27%) - pain, 1; ulcer infection, 1; possible allergy,
1; dressing leakage, 1; misdiagnosis, 1; participant default, 1
Group 2 (alginate dressing): 6/18 (33%) - pain, 4; ulcer infection, 2
Note: pain, ulcer infection and possible allergy classified by trial authors as adverse events
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Eligible patients were allocated
randomly to treatment with either the al-
ginate or Granuflex.”
Comment: sequence generation method
not reported
Allocation concealment (selection bias) Unclear risk Comment: allocationmethod not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “It was an open, randomised, par-
allel group trial . . . “
Comment: no statement regarding blind-
ing of participants or study personnel
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quote: “It was an open, randomised, par-
allel group trial . . . ”
Comment: no statement regarding blinded
outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “Statistical analysis was carried out
on results from patients who completed the
trial . . . ”
Quote: “Twelve patients were withdrawn
before completion, six on the alginate and
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Smith 1994 (Continued)
six on Granuflex . . . ”
Comment: the analysis did not include all
randomised participants
Selective reporting (reporting bias) High risk Comment: mean number of dressing
changes assessed over 2-week periods, but
was not reported as such (e.g. “one or two
alginate dressings”). Did not report all out-
come categories for quality of life assess-
ment, or data for outcomes of exudate han-
dling and ease of dressing removal
Trial protocol not available (email commu-
nication with trial sponsor)
Abbreviations
> = greater than
< = less than
≤ = less than or equal to
ITT = intention-to-treat analysis
RCT = randomised controlled trial
VAS = visual analogue scale
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anonoymous 1997 Not an RCT (review article translated from German).
Barnett 1987 Animal study.
Bull 1996 Alginate dressing not the only systematic difference across treatment arms (different compression systems
used at different participating centres)
Capillas Pérez 2000 Compared moist dressings (a mix of hydrocolloids, hydrogels, and alginates) with traditional dressings.
Results not available separately for participants receiving alginate dressings. Information confirmed with
author (RCT report published in Spanish)
Chaloner 1992 Did not report sufficient information to be judged as eligible for inclusion in this review. Unable to obtain
the necessary information to make a judgement (no response to email to sent trial author)
de la Brassinne 2006 Not treatment of interest (topical agents not alginate dressings)
Dmochowska 1999 Alginate dressing not the only systematic difference across treatment groups (alginate group only received
secondary absorbant dressing)
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(Continued)
Kammerlander 2000 Did not report sufficient information to be judged as eligible for inclusion in this review. Unable to obtain
the necessary information to make a judgement (no response to email to sent trial author)
Kordestani 2008 Not an RCT (participants allocated to groups on an alternating basis)
Límová 2002 Not treatment of interest (comparison of hydrocolloid dressings)
Moody 1991 Not an RCT (single-arm trial of alginate dressings in pressure ulcers and non-healing burns)
Mulder 1995 Abstract with limited information. Full RCT report no longer available (email communication with trial
author)
Petres 1994 Abstract with limited information. Full RCT report no longer available (email communication with trial
sponsor)
Romanelli 2008 Not treatment of interest (protease-modulating matrix dressing)
Romero-Cerecero 2012 Not treatment of interest (antifungal agent).
Schulze 2001 Alginate dressing not the only systematic difference across treatment arms (alginate group only received
secondary film dressing that was changed to a sterile swab dressing for 50% of the group half-way through
the trial)
Scurr 1994 Alginate dressing not the only systematic difference across treatment arms (different secondary dressings
used in each treatment group)
Sibbald 2005 Not treatment of interest (freeze-dried alginate not dressings)
Stacey 1997 Alginate dressing not the only systematic difference across treatment arms (different compression systems
used in each treatment group)
Thomas 1989 Not an RCT (participants allocated to groups on alternating basis)
Wild 2010 Not treatment of interest (hydrocolloid dressing).
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D A T A A N D A N A L Y S E S
Comparison 1. Tegagen HG alginate dressing compared with Sorbsan alginate dressing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of ulcers healed at 6
weeks
1 20 Risk Ratio (M-H, Fixed, 95% CI) 6.0 [0.32, 111.04]
2 Score for comfort of dressing
during wear time at 6 weeks
1 19 Mean Difference (IV, Fixed, 95% CI) -0.90 [-1.29, -0.51]
3 Score for comfort during
dressing removal at 6 weeks
1 19 Mean Difference (IV, Fixed, 95% CI) -0.7 [-0.88, -0.52]
4 Exudate absorption score at 6
weeks
1 19 Mean Difference (IV, Fixed, 95% CI) -0.80 [-1.22, -0.38]
5 Ease of dressing removal score at
6 weeks
1 19 Mean Difference (IV, Fixed, 95% CI) -0.90 [-1.28, -0.52]
Comparison 2. Hydrocolloid dressings compared with alginate dressings
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of ulcers healed at 6
and 12 weeks
3 215 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.48, 1.31]
1.1 Healed at 6 weeks 2 84 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.14, 1.21]
1.2 Healed at 12 weeks 1 131 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.57, 1.81]
2 Change in ulcer area in mm2 at
12 weeks
1 131 Mean Difference (IV, Fixed, 95% CI) -169.56 [-613.61,
274.49]
3 Percentage change in ulcer area
at 12 weeks
1 131 Mean Difference (IV, Fixed, 95% CI) -7.64 [-37.88, 22.
60]
4 Mean wear time (days) 1 131 Mean Difference (IV, Fixed, 95% CI) 0.36 [-0.29, 1.02]
5 Proportion of participants
experiencing adverse events
1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.47 [0.53, 4.03]
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Comparison 3. Plain non-adherent dressings compared with alginate dressings
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of ulcers healed at 12
weeks
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.86, 1.36]
Analysis 1.1. Comparison 1 Tegagen HG alginate dressing compared with Sorbsan alginate dressing,
Outcome 1 Proportion of ulcers healed at 6 weeks.
Review: Alginate dressings for venous leg ulcers
Comparison: 1 Tegagen HG alginate dressing compared with Sorbsan alginate dressing
Outcome: 1 Proportion of ulcers healed at 6 weeks
Study or subgroup
Sorbsan
alginate
dressing
Tegagen HG
alg dressing Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
L mov 2003 2/9 0/11 100.0 % 6.00 [ 0.32, 111.04 ]
Total (95% CI) 9 11 100.0 % 6.00 [ 0.32, 111.04 ]
Total events: 2 (Sorbsan alginate dressing), 0 (Tegagen HG alg dressing)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Tegagen HG Favours Sorbsan
52Alginate dressings for venous leg ulcers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.2. Comparison 1 Tegagen HG alginate dressing compared with Sorbsan alginate dressing,
Outcome 2 Score for comfort of dressing during wear time at 6 weeks.
Review: Alginate dressings for venous leg ulcers
Comparison: 1 Tegagen HG alginate dressing compared with Sorbsan alginate dressing
Outcome: 2 Score for comfort of dressing during wear time at 6 weeks
Study or subgroup
Tegagen HG
alginate
dressing
Sorbsan
alginate
dressing
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L mov 2003 10 1.2 (0.35) 9 2.1 (0.5) 100.0 % -0.90 [ -1.29, -0.51 ]
Total (95% CI) 10 9 100.0 % -0.90 [ -1.29, -0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.50 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Tegagen Favours Sorbsan
Analysis 1.3. Comparison 1 Tegagen HG alginate dressing compared with Sorbsan alginate dressing,
Outcome 3 Score for comfort during dressing removal at 6 weeks.
Review: Alginate dressings for venous leg ulcers
Comparison: 1 Tegagen HG alginate dressing compared with Sorbsan alginate dressing
Outcome: 3 Score for comfort during dressing removal at 6 weeks
Study or subgroup
Tegagen HG
alginate
dressing
Sorbsan
alginate
dressing
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L mov 2003 10 1.2 (0.22) 9 1.9 (0.19) 100.0 % -0.70 [ -0.88, -0.52 ]
Total (95% CI) 10 9 100.0 % -0.70 [ -0.88, -0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.44 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Tegagen Favours Sorbsan
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Analysis 1.4. Comparison 1 Tegagen HG alginate dressing compared with Sorbsan alginate dressing,
Outcome 4 Exudate absorption score at 6 weeks.
Review: Alginate dressings for venous leg ulcers
Comparison: 1 Tegagen HG alginate dressing compared with Sorbsan alginate dressing
Outcome: 4 Exudate absorption score at 6 weeks
Study or subgroup
Tegagen HG
alginate
dressing
Sorbsan
alginate
dressing
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L mov 2003 10 1.3 (0.45) 9 2.1 (0.48) 100.0 % -0.80 [ -1.22, -0.38 ]
Total (95% CI) 10 9 100.0 % -0.80 [ -1.22, -0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.74 (P = 0.00019)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Tegagen Favours Sorbsan
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Analysis 1.5. Comparison 1 Tegagen HG alginate dressing compared with Sorbsan alginate dressing,
Outcome 5 Ease of dressing removal score at 6 weeks.
Review: Alginate dressings for venous leg ulcers
Comparison: 1 Tegagen HG alginate dressing compared with Sorbsan alginate dressing
Outcome: 5 Ease of dressing removal score at 6 weeks
Study or subgroup
Tegagen HG
alginate
dressing
Sorbsan
alginate
dressing
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
L mov 2003 10 1.1 (0.16) 9 2 (0.56) 100.0 % -0.90 [ -1.28, -0.52 ]
Total (95% CI) 10 9 100.0 % -0.90 [ -1.28, -0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.65 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours Tegagen Favours Sorbsan
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Analysis 2.1. Comparison 2 Hydrocolloid dressings compared with alginate dressings, Outcome 1
Proportion of ulcers healed at 6 and 12 weeks.
Review: Alginate dressings for venous leg ulcers
Comparison: 2 Hydrocolloid dressings compared with alginate dressings
Outcome: 1 Proportion of ulcers healed at 6 and 12 weeks
Study or subgroup Alginate dressing
Hydrocolloid
dressing Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Healed at 6 weeks
Armstrong 1997 2/23 6/21 23.5 % 0.30 [ 0.07, 1.35 ]
Smith 1994 2/18 4/22 13.5 % 0.61 [ 0.13, 2.96 ]
Subtotal (95% CI) 41 43 36.9 % 0.42 [ 0.14, 1.21 ]
Total events: 4 (Alginate dressing), 10 (Hydrocolloid dressing)
Heterogeneity: Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
2 Healed at 12 weeks
Harding 2001 17/65 17/66 63.1 % 1.02 [ 0.57, 1.81 ]
Subtotal (95% CI) 65 66 63.1 % 1.02 [ 0.57, 1.81 ]
Total events: 17 (Alginate dressing), 17 (Hydrocolloid dressing)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 106 109 100.0 % 0.79 [ 0.48, 1.31 ]
Total events: 21 (Alginate dressing), 27 (Hydrocolloid dressing)
Heterogeneity: Chi2 = 2.40, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 2.07, df = 1 (P = 0.15), I2 =52%
0.01 0.1 1 10 100
Favours hydrocolloid Favours alginate
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Analysis 2.2. Comparison 2 Hydrocolloid dressings compared with alginate dressings, Outcome 2 Change in
ulcer area in mm2 at 12 weeks.
Review: Alginate dressings for venous leg ulcers
Comparison: 2 Hydrocolloid dressings compared with alginate dressings
Outcome: 2 Change in ulcer area in mm
2
at 12 weeks
Study or subgroup Hydrocolloid dressing Alginate dressing
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Harding 2001 66 -516.86 (1202.72) 65 -347.3 (1382.69) 100.0 % -169.56 [ -613.61, 274.49 ]
Total (95% CI) 66 65 100.0 % -169.56 [ -613.61, 274.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
-500 -250 0 250 500
Favours hydrocolloid Favours alginate
Analysis 2.3. Comparison 2 Hydrocolloid dressings compared with alginate dressings, Outcome 3
Percentage change in ulcer area at 12 weeks.
Review: Alginate dressings for venous leg ulcers
Comparison: 2 Hydrocolloid dressings compared with alginate dressings
Outcome: 3 Percentage change in ulcer area at 12 weeks
Study or subgroup Hydrocolloid dressing Alginate dressing
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Harding 2001 66 -38.18 (92.36) 65 -30.54 (84.08) 100.0 % -7.64 [ -37.88, 22.60 ]
Total (95% CI) 66 65 100.0 % -7.64 [ -37.88, 22.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours hydrocolloid Favours alginate
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Analysis 2.4. Comparison 2 Hydrocolloid dressings compared with alginate dressings, Outcome 4 Mean
wear time (days).
Review: Alginate dressings for venous leg ulcers
Comparison: 2 Hydrocolloid dressings compared with alginate dressings
Outcome: 4 Mean wear time (days)
Study or subgroup Hydrocolloid dressing Alginate dressing
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Harding 2001 66 3.632 (1.878) 65 3.27 (1.944) 100.0 % 0.36 [ -0.29, 1.02 ]
Total (95% CI) 66 65 100.0 % 0.36 [ -0.29, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours alginate Favours hydrocolloid
Analysis 2.5. Comparison 2 Hydrocolloid dressings compared with alginate dressings, Outcome 5
Proportion of participants experiencing adverse events.
Review: Alginate dressings for venous leg ulcers
Comparison: 2 Hydrocolloid dressings compared with alginate dressings
Outcome: 5 Proportion of participants experiencing adverse events
Study or subgroup Alginate dressing
Hydrocolloid
dressing Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Smith 1994 6/18 5/22 100.0 % 1.47 [ 0.53, 4.03 ]
Total (95% CI) 18 22 100.0 % 1.47 [ 0.53, 4.03 ]
Total events: 6 (Alginate dressing), 5 (Hydrocolloid dressing)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours alginate Favours hydrocolloid
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Analysis 3.1. Comparison 3 Plain non-adherent dressings compared with alginate dressings, Outcome 1
Proportion of ulcers healed at 12 weeks.
Review: Alginate dressings for venous leg ulcers
Comparison: 3 Plain non-adherent dressings compared with alginate dressings
Outcome: 1 Proportion of ulcers healed at 12 weeks
Study or subgroup Alginate dressing Plain non-adherent Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Moffatt 1992 26/30 24/30 100.0 % 1.08 [ 0.86, 1.36 ]
Total (95% CI) 30 30 100.0 % 1.08 [ 0.86, 1.36 ]
Total events: 26 (Alginate dressing), 24 (Plain non-adherent)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours non-adherent Favours alginate
A D D I T I O N A L T A B L E S
Table 1. Outcome data reported by included trials: primary (healing) outcomes
Armstrong 1997 Number of ulcers healed at 6 weeks:
Group 1 (hydrocolloid dressing): 6/21 (29%)
Group 2 (alginate dressing): 2/23 (9%)
P value for between-group difference not reported.
Change in ulcer size - median change in area:
Group 1 (hydrocolloid dressing): -205 mm2
Group 2 (alginate dressing): -162 mm2
The trial authors reported that the between-group difference was not statistically significant. P value not reported.
Change in ulcer size - median percentage change in ulcer area:
Group 1 (hydrocolloid dressing): -42%
Group 2 (alginate dressing): -26%
The trial authors reported that the between-group difference was not statistically significant. P value not reported.
Review authors’ comment: there was a reporting discrepancy between primary and secondary references for this
outcome. The respective values in the secondary reference were -30.5% and -28.1%
Harding 2001 Time to healing days - mean (SD) [median (range)] (analysis based on healed participants only):
Group 1 (hydrocolloid dressing): 41.823 days (SD 21.302) [42 (14 to 87)]; n = 17
Group 2 (alginate dressing): 56.588 days (SD 21.569) [56 (14 to 85)]; n = 17
Reported P value for between-group difference in means = 0.053
P = 0.05 (log rank test) for difference in Kaplan-Meier survival curves (analysis based on all randomised patients)
Number of ulcers healed at 12 weeks:
Group 1 (hydrocolloid dressing): 17/66 (26%)
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Table 1. Outcome data reported by included trials: primary (healing) outcomes (Continued)
Group 2 (alginate dressing): 17/65 (26%)
P value for between-group difference not reported
Change in ulcer area mm2 - mean (SD) [median (range)]:
Group 1 (hydrocolloid dressing): -516.86 mm2 (SD 1202.72) [-301.13 (-2494.84 to 5285.82)]; n = 66
Group 2 (alginate dressing): -347.30 mm2 (SD 1382.69) [-132.83 (-5144.08 to 5946.24)]; n = 65
P value for between-group difference in means P = 0.48, reported by trial authors
Percentage change in ulcer area - mean (SD) [median (range)]:
Group 1 (hydrocolloid dressing): -38.18% (SD 92.36) [-67.67 (374.84 to -100.00)]; n = 66
Group 2 (alginate dressing): -30.54% (SD 84.08) [-43.33 (411.74 to -100.00)]; n = 65
P value for between-group difference in means = 0.64, reported by trial authors
Límová 2003 Number of ulcers healed at 6 weeks:
Group 1 (alginate dressing, Tegagen ™ HG): 0/11 (0%)
Group 2 (alginate dressing, Sorbsan®): 2/9 (22%)
P value for between-group difference not reported.
Mean percentage change in wound area at 6 weeks:
Group 1 (alginate dressing, Tegagen ™ HG): -33.7%, n = 10
Group 2 (alginate dressing, Sorbsan®): -29.6%, n = 9
The trial authors reported a P value of 0.88 for between-group difference
Moffatt 1992 Time to healing/number of ulcers healed at 12 weeks:
Group 1 (plain non-adherent dressing): 24/30 (80%)
Group 2 (alginate dressing): 26/30 (87%)
P value for between-group difference not reported
The trial authors reported that results were similar for cumulative proportions healed estimated using life table
analysis (no data or P value for between-group difference presented)
Smith 1994 Number of ulcers healed at 6 weeks:
Group 1 (hydrocolloid dressing): 4/22 (18%)
Group 2 (alginate dressing): 2/18 (11%)
P value for between-group difference not reported
Mean percentage change in ulcer area:
Group 1 (hydrocolloid dressing): -57.1
Group 2 (alginate dressing): -34.9
The trial authors reported that the between-group difference was not statistically different. P value not reported
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Table 2. Outcome data reported by included trials - secondary outcomes
Armstrong 1997 Mean wear time days:
Group 1 (hydrocolloid dressing): 4.112 days
Group 2 (alginate dressing): 3.051 days
The trial authors reported a between-group difference of 1.029 days (95% CI 0.385 to 1.672), and that the
difference was statistically significant in favour of Group 1 but the P value was not reported. Reviewer authors’
comment: the difference in means reported by the trial authors does not follow from the mean values for each
group
Number participants achieving a 7-day wear time on at least one occasion:
Group 1 (hydrocolloid dressing): 9/21 (43%)
Group 2 (alginate dressing): 3/23 (13%)
The trial authors reported that the between-groupdifference (30%, 95%CI5%to 55%)was statistically significant
but P value not reported
Cost to heal one ulcer:
Group 1 (hydrocolloid dressing): GBP 237.66 (total direct and indirect costs = GBP 1425.97 for total of 6
wounds healed)
Group 2 (alginate dressing): GBP 687.31 (total direct and indirect costs = GBP 1374.61 for total of 2 wounds
healed)
Cost per wound healed calculated by review authors.
Taking into account the number of participants completely healed in each group, the trial authors reported that
the cost to achieve a healed wound using the Group 1 dressing was approximately one-third of the cost of Group
2.
Number dressing changes with no pain, mild pain, moderate pain, severe pain, excruciating pain, unable
to respond, missing data:
Group 1 (hydrocolloid dressing): (total of 192 dressing changes) 144 (75%), 38 (20%), 6 (3%), 2 (1%), 0 (0%)
, 0 (0%), 2 (1%)
Group 2 (alginate dressing): (total of 224 dressing changes) 186 (83%), 29 (13%), 8 (3.5%), 0 (0%), 0 (0)%, 0
(0%), 1 (0.5%)
Number of adverse events during the trial:
Group 1 (hydrocolloid dressing): 32 adverse events reported during the trial. 4 were related to the primary dressing
and 28 to the secondary dressing, of which 8 were attributed to maceration
Group 2 (alginate dressing): 32 adverse events reported during the trial. 3 were related to the primary dressing
and 29 to the secondary dressing, of which 9 were attributed to maceration
Harding 2001 Total number of dressing changes:
Group 1 (hydrocolloid dressing): 1093
Group 2 (alginate dressing): 1186
Mean wear time days (SD) [median (range)]:
Group 1 (hydrocolloid dressing): 3.632 days (1.878) [3 (1 to 13)]; n = 66
Group 2 (alginate dressing): 3.271 days (1.944) [3 (1 to 9)]; n = 65
The trial authors reported that the between-group difference in means was P value < 0.001
Mean number of dressing changes per healed ulcer:
Group 1 (hydrocolloid dressing): 7.4
Group 2 (alginate dressing): 12.1
P value for between-group difference not reported
Mean cost to achieve ulcer healing (based on patients healed):
Group 1 (hydrocolloid dressing): GBP 1184.09 (USD 1699.71)
Group 2 (alginate dressing): GBP 1200.73 (USD 1723.59)
Mean cost per 1cm2 reduction in ulcer size (all patients randomised):
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Table 2. Outcome data reported by included trials - secondary outcomes (Continued)
Group 1 (hydrocolloid dressing): GBP 59.22 (USD 85.01)
Group 2 (alginate dressing): GBP 92.27 (USD 132.46)
Mean cost per 10% reduction in ulcer area:
Group 1 (hydrocolloid dressing): GBP 80.15 (USD 115.06)
Group 2 (alginate dressing): GBP 104.92 (USD 150.62)
Percentage of dressing changes associated with no pain:
Group 1 (hydrocolloid dressing): 82%
Group 2 (alginate dressing): 62%
The trial authors reported that the between-group difference was statistically significant ( P value < 0.001).
Numbers of dressings not reported
Dressing performance - percentage recording “excellent” for overall ability to contain exudate:
Group 1 (hydrocolloid dressing): 44%
Group 2 (alginate dressing): 20%
Unclear whether denominator was the number of participants or the number of dressing changes
Reported P value for between-group difference = 0.002
Dressing performance - percentage recording “excellent” for overall ease of dressing removal:
Group 1 (hydrocolloid dressing): 51%
Group 2 (alginate dressing): 24%
Unclear whether denominator was the number of participants or the number of dressing changes
Reported P value for between-group difference = 0.006
Percentage of dressing changes with some adhesion to the wound bed:
Group 1 (hydrocolloid dressing): 38%
Group 2 (alginate dressing): 74%
The trial authors reported that the between-group difference was statistically significant (P value < 0.001)
Number of dressing changes not reported
Review authors’ comments: there were some minor discrepancies between numbers in main text and tables for cost
information (data frommain text were recorded here); discrepancies between primary and secondary references for
outcomes of ease of removal and exudate handling (data from primary reference recorded here); unclear whether
reported outcomes relating to pain at dressing change, exudate handling, ease of dressing removal and adhesion
were rated by participants or investigators (or both)
Límová 2003 Total number of dressing changes over the course of the trial:
Group 1 (alginate dressing, Tegagen ™ HG): 69 (65 scheduled and 4 unscheduled)
Group 2 (alginate dressing, Sorbsan®): 61 (60 scheduled and 1 unscheduled)
Mean (SD) comfort score during wear over number of visits:
Group 1 (alginate dressing, Tegagen ™ HG): 1.2 (SD 0.35) over 55 visits; n = 10
Group 2 (alginate dressing, Sorbsan®): 2.1 (SD 0.50) over 51 visits; n = 9
The trial authors reported a P value of 0.0005 for the between-group difference
Mean (SD) comfort score during dressing removal over number of visits:
Group 1 (alginate dressing, Tegagen ™ HG): 1.2 (SD 0.22) over 55 visits; n = 10
Group 2 (alginate dressing, Sorbsan®): 1.9 (SD 0.19) over 51 visits; n = 9
The trial authors reported a P value of 0.003 for the between-group difference
Percentage of visits where necrotic tissue was observed:
Group 1 (alginate dressing, Tegagen ™ HG): 59.7% of 55 visits; n = 10
Group 2 (alginate dressing, Sorbsan®): 68.9% of 51 visits; n = 9
The trial authors reported a P value of 0.57 for the between-group difference
Percentage of visits where debridement was required:
Group 1 (alginate dressing, Tegagen ™ HG): 18.7% of 55 visits; n = 10
Group 2 (alginate dressing, Sorbsan®): 40.7% of 51 visits; n = 9
62Alginate dressings for venous leg ulcers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Outcome data reported by included trials - secondary outcomes (Continued)
The trial authors reported a P value of 0.18 for the between-group difference
Mean improvement in amount of necrotic tissue (lower score is better):
Group 1 (alginate dressing, Tegagen ™ HG): 2.5 over 55 visits; n = 10
Group 2 (alginate dressing, Sorbsan®): 1.5 over 51 visits; n = 9
The trial authors reported a P value of 0.38 for the between-group difference
Mean (SD) exudate absorption score over number of visits (lower score better):
Group 1 (alginate dressing, Tegagen ™ HG): 1.3 (SD 0.45) over 55 visits; n = 10
Group 2 (alginate dressing, Sorbsan®): 2.1 (SD 0.48) over 51 visits; n = 9
The trial authors reported a P value of 0.002 for the between-group difference
Percentage of clinic visits with medium or large amount of exudate observed:
Group 1 (alginate dressing, Tegagen ™ HG): 71.7% of 55 visits; n = 10
Group 2 (alginate dressing, Sorbsan®): 86.3% of 51 visits; n = 9
The trial authors reported a P value of 0.25 for the between-group difference
Mean (SD) ease of removal score over number of visits (lower is better):
Group 1 (alginate dressing, Tegagen ™ HG): 1.1 (SD 0.16) over 55 visits; n = 10
Group 2 (alginate dressing, Sorbsan®): 2.0 (SD 0.56) over 51 visits; n = 9
The trial authors reported a P value of 0.002 for the between-group difference
Proportion of participants reporting dressing adherence to the wound bed:
Group 1 (alginate dressing, Tegagen ™ HG): 0%
Group 2 (alginate dressing, Sorbsan®): 27.8%
The trial authors reported that the average percentage of dressing changes with adherence to the wound bed was
significantly less in Group 1 (P value < 0.05)
Percentageof clinic visitswith observation ofperi-wound skin asmacerated, denuded, requiringmedication:
Group 1 (alginate dressing, Tegagen ™ HG): 36.0%, 9.0%, 31.3%
Group 2 (alginate dressing, Sorbsan®): 54.4%, 31.9%, 65.2%
Reported P values for between-group difference: macerated skin P value 0.30; denuded skin P value 0.04, medi-
cation required P value 0.07
Moffatt 1992 None reported
Smith 1994 Proportion of participants “improved remarkably” in quality of life at week 6:
Group 1 (hydrocolloid dressing): 42.9%
Group 2 (alginate dressing): 40.0%
The trial authors did not report the number of participants completing the quality of life assessment. P value for
between-group difference not reported. There was a reporting discrepancy between “improved remarkably” and
the pre-defined categories for this outcome (deteriorated markedly, deteriorated somewhat, no change, improved
somewhat or improved markedly)
Number of dressings used per week:
Group 1 (hydrocolloid dressing): 1-3
Group 2 (alginate dressing): 1-2
Wear time:
The trial authors reported that both dressings were equivalent in terms of wear time, but no data by group or P
value for between-group difference were reported
Mean total approximate cost of materials:
Group 1 (hydrocolloid dressing): GBP 431.73
Group 2 (alginate dressing): GBP 364.08
P value for between-group difference not reported
Mean ulcer pain score over past 2 weeks at 6 weeks:
Group 1 (hydrocolloid dressing): 1.46
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Table 2. Outcome data reported by included trials - secondary outcomes (Continued)
Group 2 (alginate dressing): 2.15
The trial authors reported that the between-group difference was not statistically significant. P value not reported
Change from baseline in mean ulcer pain score over past 2 weeks at 6 weeks:
Group 1 (hydrocolloid dressing): -3.28
Group 2 (alginate dressing): -2.71
Estimated by review authors
Mean pain score at dressing change at week 6:
Group 1 (hydrocolloid dressing): 1.73
Group 2 (alginate dressing): 2.16
P value for between-group difference not reported
Change from baseline in mean pain score at dressing change at 6 weeks:
Not reported and reviewer unable to estimate as data at week 6 only reported (no baseline)
Proportion of participants reporting no sleep disturbance due to pain at week 2 and week 6:
Group 1 (hydrocolloid dressing): 31.25%, 78.6%
Group 2 (alginate dressing): 8.8%, 40.0%
The trial authors did not report whether the proportions were for all participants enrolled or only those completing
the trial. Reported P value for between-group difference = 0.0721, but unclear to which time point this refers or
if it is for the test across time points
Dressing performance (exudate handling):
The trial authors reported that the Group 2 dressing was “slightly superior” in terms of ability to contain exudate.
However, no data by group or P value for between-group difference were reported
Proportion of participants reporting ‘excellent’ for ease of dressing removal:
Group 1 (hydrocolloid dressing): 56.3%
Group 2 (alginate dressing): 8.3%
The trial authors did not report raw numbers and the denominator was not clear. Reported P value for between-
group difference was < 0.001. The trial authors reported that the Group 2 dressing often needed to be soaked off
the ulcer.
Number participants experiencing adverse events:
Group 1 (hydrocolloid dressing): 5/22 (23%) (withdrawals: pain, 1; ulcer infection, 1; possible allergy, 1; not
thought to warrant withdrawal - wound infection, 1; pain and erythema at the final visit, 1)
Group 2 (alginate dressing): 6/18 (33%) (withdrawals: pain, 4; ulcer infection, 2)
A P P E N D I C E S
Appendix 1. Glossary
The source for all definitions is The Free Dictionary 2015.
Aetiology: the underlying cause of diseases and disorders.
Autolytic: the destruction of tissues or cells of an organism by the action of substances, such as enzymes, that are produced within the
organism.
Debride/debridement: the removal of foreign material and dead or damaged tissue from a wound.
Exudate: fluid, which leaks out of a wound.
Fibrinolytic therapy: the use of special drugs to break up blood clots.
Haemodynamic(s): the study of the forces involved in the circulation of blood.
Haemostatic: retarding or stopping bleeding.
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Macerate/maceration: the softening and breaking down of skin resulting from prolonged exposure to moisture.
Slough: a layer or mass of dead tissue separated from surrounding living tissue, as in a wound, a sore, or an inflammation.
Vasoactive: causing constriction or dilation of blood vessels.
Appendix 2. British National Formulary categories of dressings
Basic wound contact dressings
Low-adherence dressings
Low-adherence dressings are usually cotton pads that are placed directly in contact with the wound. These dressings can be used as
interface layers under secondary absorbent dressings and are suitable for clean, granulating, lightly exuding wounds without necrosis;
they protect the wound bed from direct contact with secondary dressings. Variants include tulle dressings (manufactured from cotton or
viscose fibres impregnated with soft white or yellow paraffin) and knitted viscose dressings (BNF 2015). Examples include Atrauman®
(Hartmann) and Tricotex® (Smith and Nephew).
Absorbent dressings
Absorbent dressings have an absorbent cellulose or polymer wadding layer and are suitable for use on moderately to heavily exuding
wounds. These may be applied directly to the wound and may be used as secondary absorbent layers in the management of heavily
exuding wounds (BNF 2015). Examples include DryMax® Extra (Aspen Medical) and KerraMax® (Ark Therapeutics).
Advanced wound dressings
Hydrogel dressings
Hydrogel dressings consist of cross-linked insoluable polymers (i.e. starch or carboxymethylcellulose) and up to 96% water. They are
supplied in flat sheets, or as an amorphous hydrogel or as beads. These dressings are generally used to donate liquid to dry, sloughy
wounds and facilitate autolytic debridement of necrotic tissue. Some also have the ability to absorb very small amounts of exudate.
A secondary, non-absorbent dressing is required with these dressings (BNF 2015). Examples include ActiFormCool® (Activa) and
Intrasite Hydrosorb® (Hartmann).
Vapour-permeable films and dressings
Vapour-permeable dressings come in the form of a transparent film, usually with an adhesive base, which is applied to the wound.
Vapour-permeable films and membranes allow the passage of water vapour and oxygen but are impermeable to water and micro-
organisms. They are suitable for lightly-exuding wounds, but not for infected, large, heavily-exuding wounds. Most commonly, they are
used as a secondary dressing over alginates or hydrogels (BNF 2015). Examples include OpSite® (Smith and Nephew) and Tegaderm®
(3M).
Soft polymer dressings
Dressings with soft polymer, often a soft silicone polymer, in a non-adherent or gently-adherent layer are suitable for use on lightly-
to moderately-exuding wounds. For moderately- to heavily-exuding wounds, an absorbent secondary dressing can be added, or a soft
polymer dressing with an absorbent pad can be used (BNF 2015). Examples include Mepilex® (Mölnlycke) and Urgotul® (Urgo).
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Hydrocolloid dressings
Hydrocolloid dressings are occlusive dressings usually composed of a hydrocolloidmatrix bonded onto a vapour-permeable film or foam
backing. When in contact with wound exudate these dressings form a gel to facilitate rehydration in lightly- to moderately-exuding
wounds (BNF 2015). Examples include DuoDERM® Extra Thin (ConvaTec) and Tegaderm® Hydrocolloid (3M).
Foam dressings
Foam dressings contain hydrophilic foam and are suitable for all types of exuding wounds. They vary in their ability to absorb exudates;
some are suitable only for lightly to moderately exuding wounds, while others have a greater fluid-handling capacity. These can be used
in combination with other primary wound contact dressings, but are usually placed over ulcers prior to the application of compression
bandages or hosiery, with the intention of promoting healing, and preventing the bandages from sticking to the wound. Saturated foam
dressings can cause maceration of healthy skin if left in contact with the wound. If used under compression bandaging or compression
garments, the fluid-handling capacity of foam dressings may be reduced (BNF 2015). Examples include and Biatain® Non-Adhesive
(Coloplast) and Tielle® Plus (Systagenix).
Alginate dressings
Alginate dressings are available as flat, freeze-dried porous sheets, or as flexible fibre dressings (e.g. packing tape), designed for packing
cavity wounds. The base constituents include calcium alginate or calcium sodium alginate, derived from brown seaweed. Alginate
dressings are designed to form a soft gel once in contact with wound exudate. Purported benefits of alginate dressings include high
absorbency of fluid from moderately to heavily exuding wounds and the ability to maintain a moist wound environment, thereby
promoting autolytic debridement (the body’s own process of breaking down dead tissue lying on top of the wound bed). Calcium ions
present in the dressings help to control bleeding by aiding blood clotting; a potential disadvantage is that blood clots may cause the
dressing to adhere to the wound surface. Alginate dressings are designed to function most effectively in a moist environment, and are
not suitable for use with dry wounds, or those covered with hard, necrotic tissue; heavy bleeding is a contraindication to use (BNF
2015; Boateng 2008). In the UK, alginate dressings are common to many wound care formularies, where they are often recommended
for the management of wounds with moderate to high amounts of exudate. Examples of alginate dressings currently available in the
UK include Algosteril® (Smith and Nephew) and Tegaderm® Alginate (3M).
Capillary-action dressings
Capillary-action dressings consist of an absorbent core of hydrophilic fibres held between two low-adherent wound-contact layers to
ensure no fibres are shed on to the wound surface. Wound exudate is taken up by the dressing and retained within the highly absorbent
central layer. Capillary-action dressings are suitable for use on all types of exuding wounds, but particularly on sloughy wounds where
removal of fluid from the wound aids debridement (BNF 2015). Examples include Advadraw® (Advancis) and Vacutex® (Protex).
Odour-absorbant dressings
Dressings containing activated charcoal are used to absorb odour from wounds. Many odour absorbent dressings are intended for use
in combination with other dressings, and are often used in conjunction with a secondary dressing to improve absorbency (BNF 2015).
Examples include CarboFLEX® (ConvaTec) and CliniSorb® Odour Control Dressings (CliniMed).
Antimicrobial dressings
Honey
Medical-grade honey has antimicrobial and anti-inflammatory properties and can be used for acute or chronic wounds. It is available
in sheet-dressing form or as a honey-base topical application applied directly to the wound and covered with a primary low-adherence
wound dressing (BNF 2015). Examples include Medihoney® (Medihoney) and Mesitran® (Aspen Medical).
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Iodine
Iodine has a long history of use as a skin and wound disinfectant. It is thought to have a wide spectrum of antimicrobial activity but
is deactivated by wound exudate. There are currently two types of iodine-based preparations used in wound management: povidone
iodine and cadexomer iodine. Povidone iodine is available as various topical applications (solution, ointment and spray) and as an
impregnated wound dressing. The impregnated dressing may be used as a wound contact layer for abrasions and superficial burns,
and has also been used with chronic wounds (BNF 2015; Jeffcoate 2009). An example is Inadine® (Systagenix). Cadexomer iodine
is available as different topical applications (paste, ointment and powder) and is used to absorb exudate and for debridement (BNF
2015). Examples include Iodoflex® (Smith and Nephew) and Iodosorb® (Smith and Nephew).
Silver
Antimicrobial dressings containing silver are available as: low-adherent dressings, with knitted fabric of activated charcoal, soft polymer
dressings, hydrocolloid dressings, foam dressings and alginate dressings. Silver ions exert an antimicrobial effect in the presence of
wound exudate. Antimicrobial dressings containing silver should be used only when infection is suspected on the basis of clinical signs
or symptoms (BNF 2015). Examples include Acticoat® (Smith and Nephew), Aquacel® Ag (ConvaTec) and Biatain® Ag (Coloplast).
Other antimicrobial dressings
A number of dressings that are impregnated with other antimicrobial agents, such as chlorhexidine and polyhexanide, are also available
(BNF 2015). Examples include chlorhexidine gauze dressing, BP 1993 and Suprasorb® X + PHMB (Activa).
Specialised dressings
Protease-modulating matrix dressings
Protease-modulating matrix dressings alter the activity of proteolytic enzymes in chronic wounds (BNF 2015). Examples include
Promogran® (Systagenix) and UrgoStart® (Urgo).
Appendix 3. Search strategies for Ovid Medline, Ovid Embase and EBSCO CINAHL
Ovid Medline
1 exp Alginates/ (4449)
2 (alginate* or activheal or algisite or algosteril or curasorb or kalostat or melgisorb or seasorb or sorbalgon or sorbsan or suprasorb a
or tegaderm or tegagel or urgosorb).tw. (6053)
3 or/1-2 (6601)
4 exp Leg Ulcer/ (9728)
5 (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris).tw. (3571)
6 or/4-5 (10421)
7 3 and 6 (68)
8 randomized controlled trial.pt. (238104)
9 controlled clinical trial.pt. (39335)
10 randomized.ab. (193802)
11 placebo.ab. (90703)
12 clinical trials as topic.sh. (79028)
13 randomly.ab. (133232)
14 trial.ti. (71766)
15 or/8-14 (538944)
16 (animals not (humans and animals)).sh. (1600596)
17 15 not 16 (490866)
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18 7 and 17 (21)
19 2012*.ed. (680299)
20 18 and 19 (3)
Ovid Embase
1 exp alginic acid/ (8396)
2 (alginate* or activheal or algisite or algosteril or curasorb or kalostat or melgisorb or seasorb or sorbalgon or sorbsan or suprasorb a
or tegaderm or tegagel or urgosorb).tw. (9024)
3 or/1-2 (11076)
4 exp leg ulcer/ (5951)
5 (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris).tw. (5370)
6 or/4-5 (7825)
7 3 and 6 (121)
8 Randomized controlled trials/ (22788)
9 Single-Blind Method/ (15232)
10 Double-Blind Method/ (84730)
11 Crossover Procedure/ (31212)
12 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or assign$ or allocat$ or volunteer$).ti,ab. (920231)
13 (doubl$ adj blind$).ti,ab. (88524)
14 (singl$ adj blind$).ti,ab. (9443)
15 or/8-14 (952716)
16 animal/ (716985)
17 human/ (8455793)
18 16 not 17 (478469)
19 15 not 18 (920958)
20 7 and 19 (27)
21 2012*.em. (1182739)
22 20 and 21 (1)
EBSCO CINAHL
S7S3 AND S6
S6S4 OR S5
S5TI ( alginate* or activheal or algisite or algosteril or curasorb or kalostat or melgisorb or seasorb or sorbalgon or sorbsan or suprasorb
a or tegaderm or tegagel or urgosorb ) OR AB ( alginate* or activheal or algisite or algosteril or curasorb or kalostat or melgisorb or
seasorb or sorbalgon or sorbsan or suprasorb a or tegaderm or tegagel or urgosorb )
S4(MH “Alginates”)
S3S1 OR S2
S2TI (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris) OR AB (varicose ulcer*
or venous ulcer* or leg ulcer* or stasis ulcer* or crural ulcer* or ulcus cruris or ulcer cruris)
S1(MH “Leg Ulcer+”)
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Appendix 4. Dressing manufacturers contacted regarding ongoing or recently completed trials of
alginate dressings
3M
Activa
Aspen Medical
Coloplast
ConvaTec
Covidien
Hartmann
MedLogic
Mölnlycke
Smith & Nephew Healthcare
Urgo
Appendix 5. Data extraction form
Trial identifier First author and year (country where trial undertaken)
Methods Design (number of study centres): e.g. pragmatic RCT (5 study centres)
Sample size calculation: yes or no, if yes, summarise estimation details
Treatment setting.
Ethical approval reported: yes or no.
Informed consent reported: yes or no.
Participant characteristics at baseline Number of patients randomised overall and recruitment setting:
Inclusion criteria:
Ulcer diagnosis method: e.g. Doppler
Exclusion criteria:
Unit of randomisation/analysis:
Numbers randomised per treatment group:
Group 1 (comparator dressing): xx participants/limbs/ulcers
Group 2 (alginate dressing): xx participants/limbs/ulcers
Participant age in years - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Number (%) male:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Number (%) of participants with co-morbidities such as diabetes:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Number (%) of participants with ulcer aetiology venous/mixed/arterial/other:
Group 1 (comparator dressing):
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(Continued)
Group 2 (alginate dressing):
ABPI:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Number (%) of participants according to different categories of mobility (e.g. fully mobile,
walks with aid, confined to bed or wheelchair):
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Health-related quality of life score (instrument) - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Number (%) of participants with previous history of leg ulceration:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Ulcer surface area (in, e.g. cm2) - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Ulcer duration (in, e.g. months) - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Number (%) of participants with ulcer infection:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Ulcer-related pain score (instrument) - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Percentage of sloughy or necrotic material on the wound bed - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Participant baseline exudate levels (instrument) - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Comments:
Intervention characteristics Group 1: description of comparator dressing, e.g. hydrocolloid dressing (proprietary name,
manufacturer)
Group 2: description of alginate dressing (proprietary name, manufacturer)
Details of other care, common to all treatment groups (e.g. wound cleansing, debridement,
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(Continued)
compression, also planned frequency of dressing changes)
Length of treatment:
Length of follow-up:
Comments:
Outcomes Reporting of outcomes specified in the review - yes or no; if yes, give details of assessment
and statistical methods:
Time to healing:
Proportion of ulcers healed:
Change in ulcer size:
Healing rate:
Health-related quality of life:
Costs: e.g. including cost or cost-effectiveness estimations as well as measurements of resource
use such as number of dressing changes, dressing wear time and nurse time
Pain: e.g. at dressing change, in between dressing changes or over the course of treatment
Debridement: e.g. measured as percentage of sloughy or necrotic material remaining on the
wound bed
Haemostasis: management of bleeding
Dressing performance - exudate handling:
Dressing performance - adherence/sticking to wound bed:
Adverse events - number per group together with descriptions:
Other outcomes assessed by the trial:
Outcome data Time to healing (in, e.g. weeks) - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Number (%) of ulcers healed at (state time point):
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Change in ulcer size (either as absolute change, e.g. in cm2 or as % change relative to baseline)
- mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Healing rate (e.g. cm2 per week) - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Health-related quality of life score - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Cost or other resource use estimation - mean (SD) [median (range)]:
Group 1 (comparator dressing):
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(Continued)
Group 2 (alginate dressing):
Ulcer-related pain score - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Debridement, e.g. percentage of sloughy or necrotic material on the wound bed - mean (SD)
[median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Haemostasis, as reported:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Dressing performance (exudate handling) exudate levels/score - mean (SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Dressing performance (adherence/sticking to wound bed), using score as reported - mean
(SD) [median (range)]:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Number (%) patients experiencing adverse events (with description of events):
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Comments:
Notes Name of trial sponsor:
Trial registration number:
Number (%) participants withdrawing and reasons:
Group 1 (comparator dressing):
Group 2 (alginate dressing):
Appendix 6. ’Risk of bias’ criteria
1. Was the allocation sequence randomly generated?
Low risk of bias: the investigators describe a random component in the sequence generation process such as: referring to a random
number table; using a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias: the investigators describe a non-random component in the sequence generation process. Usually, the description
would involve some systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated
by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear risk of bias: insufficient information about the sequence generation process to permit judgement of low or high risk of bias.
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2. Was the treatment allocation adequately concealed?
Low risk of bias: participants and investigators enrolling participants could not foresee assignment because one of the following, or
an equivalent method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled
randomisation); sequentially-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
High risk of bias: participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection
bias, such as allocation based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes
were used without appropriate safeguards (e.g. envelopes were unsealed or non-opaque or not sequentially-numbered); alternation or
rotation; date of birth; case record number; any other explicitly unconcealed procedure.
Unclear risk of bias: insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method
of concealment is not described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment
envelopes is described, but it remains unclear whether envelopes were sequentially-numbered, opaque and sealed.
3. Blinding of participants and personnel - was knowledge of the allocated interventions adequately prevented
during the study?
Low risk of bias: no blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be
influenced by lack of blinding or blinding of participants and key study personnel ensured, and unlikely that the blinding could have
been broken.
High risk of bias: no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding or blinding of
key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be
influenced by lack of blinding.
Unclear risk of bias: insufficient information to permit judgement of ‘low risk’ or ‘high risk’, or the study did not address this outcome.
4. Blinding of outcome assessment - was knowledge of the allocated interventions adequately prevented during
the study?
Low risk of bias: no blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be
influenced by lack of blinding or blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.
High risk of bias: no blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding or
blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be
influenced by lack of blinding.
Unclear risk of bias: insufficient information to permit judgement of ‘low risk’ or ’high risk’, or the study did not address this outcome.
5. Were incomplete outcome data adequately addressed?
Low risk of bias: no missing outcome data, or reasons for missing outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias), or missing outcome data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; or (for dichotomous outcome data), the proportion of missing outcomes compared with observed
event risk not enough to have a clinically relevant impact on the intervention effect estimate; or (for continuous outcome data), plausible
effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant
impact on observed effect size; or missing data have been imputed using appropriate methods.
High risk of bias: reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons
for missing data across intervention groups; or (for dichotomous outcome data), the proportion of missing outcomes compared with
observed event risk enough to induce clinically relevant bias in intervention effect estimate; or (for continuous outcome data), plausible
effect size (difference in means or standardised difference in means) among missing outcomes enough to induce clinically relevant
bias in observed effect size; or ‘as-treated’ analysis done with substantial departure of the intervention received from that assigned at
randomisation, or potentially inappropriate application of simple imputation.
Unclear risk of bias: insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number
randomised not stated, no reasons for missing data provided), or the study did not address this outcome.
73Alginate dressings for venous leg ulcers (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
6. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias: either the trial protocol is available and all of the pre-specified outcomes that are in the protocol have been reported
in the pre-specified manner or, if the protocol is not available, it is clear that the published report includes all outcomes in the results
section that are described as being assessed in the methods section.
High risk of bias: if the trial protocol is available either, not all of the pre-specified outcomes that are in the protocol are reported, or
one or more outcomes are reported using measurements, analysis methods or subsets of the data that are not pre-specified; or one or
more reported outcomes were not pre-specified (unless there is justification for their reporting, such as an unexpected adverse event).
If the trial protocol is not available either, not all of the trial’s outcomes have been reported in the results section that are described in
the methods section, or one or more of the outcomes is reported using measurements, analysis methods or subsets of the data (e.g. sub-
scales) that were not described in the methods section of the report; or one or more of the reported outcomes were not described in the
methods section.
Unclear risk of bias: insufficient information to permit judgement of low or high risk of bias.
WH A T ’ S N E W
Last assessed as up-to-date: 4 March 2015.
Date Event Description
19 August 2015 New citation required but conclusions have not changed Nonew trials identified, references updated, conclusions
unchanged
19 August 2015 New search has been performed First update, new search, new author joined the team.
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